document incorporate reference portion definitive proxy statement registrant annual meeting shareholder file day conclusion registrant fiscal year end december securities exchange commission pursuant regulation security exchange act amend incorporate reference iii annual report extent describe thereinbristolmyer squibb company index december item business acquisition divestiture license arrangement product intellectual property product exclusivity research development alliance marketing distribution customer competition pricing price constraint market access government regulation source availability raw material manufacturing quality assurance environmental regulation employee foreign operation bristolmyer squibb website item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure ia information executive officer ii item market registrant common stock stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum consolidate statement earning comprehensive income consolidate balance sheet consolidate statement cash flow note financial statement item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item auditor fee iv item exhibit financial statement schedule item summary signature summary abbreviate term exhibit index indicate brand name product trademark own bms specific trademark ownership information include exhibit index end form kpart item business general bristolmyers squibb company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis refer summary abbreviate term end term document november complete acquisition celgene result celgene wholly own subsidiary bristolmyer squibb company term transaction celgene shareholder receive share bristolmyer squibb common stock cash share celgene common stock hold celgene shareholder receive contingent value right cvr represent right receive cash subject achievement future regulatory milestone share celgene common stock fund cash portion merger consideration available cash include billion net proceed raise issuance new note billion borrowing term loan establish january connection acquisition base closing share price common stock november aggregate purchase price approximately billion include approximately billion cash approximately billion bristolmyer squibb common stock allow acquisition bristolmyers squibb close timely basis light concern express federal trade commission ftc celgene enter purchase agreement amgen august amgen acquire global right otezla apremilast billion connection divestiture celgene enter purchase agreement enter guarantee amgen agree guarantee payment performance celgene obligation purchase agreement november ftc accept consent order public comment allow acquisition celgene proceed subject certain condition include completion divestiture otezla amgen november divestiture otezla complete continue operate segmentbiopharmaceutical acquisition celgene additional information business segment refer item financial statement supplementary datanote accounting policy recently issue accounting standard believe combination celgene enable create lead biopharmaceutical company wellpositione address need patient cancer inflammatory immunologic cardiovascular fibrotic disease highvalue innovative medicine lead scientific capability principal strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry focus biopharmaceutical company discover develop deliver transformational medicine patient face disease area believe opportunity meaningful difference oncology solid tumor hematology immunology cardiovascular fibrosis new strategic priority combine company drive enterprise performance maximize value commercial portfolio ensure longterm sustainability pipeline combine internal external innovation establish new culture embed people strategy commit reduce debt incur connection celgene transaction plan remain focused broaden portfolio market medicine pipeline asset discussion strategy initiative refer item management discussion analysis financial condition result operation strategy compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler specialty distributor retail pharmacy hospital government entity medical profession manufacture product puerto rico significant manufacturing operation foreign country revenue come product follow therapeutic class hematology oncology cardiovascular immunology percentage revenue significant regioncountry follow year end december dollar millions united states europe rest world total revenue acquisition divestiture license arrangement acquisition divestiture license arrangement allow focus resource growth opportunity drive great longterm value significant business development activity include december complete divestiture oral solid biologic sterile product manufacturing packaging facility anagni italy catalent inc november complete acquisition celgene july complete divestiture consumer health business upsa taisho pharmaceutical co ltd november pursuant consent order accept ftc connection regulatory approval process acquisition celgene complete divestiture otezla amgen additional information relate acquisition divestiture license arrangement contain item financial statement supplementary datum note acquisition divestiture license arrangement product intellectual property product exclusivity pharmaceutical product include chemicallysynthesize small molecule drug product produce biological process call biologic small molecule drug typically administer orally eg form pill tablet drug delivery mechanism biologic typically administer patient injection intravenous infusion summary significant product include approve indication information alliance arrangement certain product refer alliance item financial statement supplementary datanote alliance revlimid revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicate treatment patient multiple myeloma revlimid single agent indicate maintenance therapy patient multiple myeloma follow autologous hematopoietic stem cell transplant revlimid receive approval indication hematological malignancy include lymphoma mds eliquis eliquis apixaban oral factor xa inhibitor target stroke prevention adult patient nvaf prevention treatment vte disorder opdivo opdivo nivolumab biological product fully human monoclonal antibody bind pd nkt cell opdivo receive approval anticancer indication include bladder blood colon head neck kidney liver lung melanoma stomach opdivoyervoy regimen approve multiple market treatment melanoma rcc crc ongoing potentially registrational study opdivo tumor type disease area monotherapy combination yervoy anticancer agent orencia orencia abatacept biological product fusion protein indicate adult patient moderately severely active ra psa indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular jia pomalystimnovid pomalystimnovid pomalidomide proprietary distinct small molecule administer orally modulate immune system biologically important target pomalystimnovid indicate patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression day completion therapy sprycel sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment patient philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate treatment child adolescent aged year year chronic phase philadelphia chromosomepositive cml yervoy yervoy ipilimumab biological product monoclonal antibody treatment patient unresectable metastatic melanoma abraxane abraxane paclitaxel albuminbound particle injectable suspension solventfree proteinbound chemotherapy product combine paclitaxel albumin proprietary nab technology platform treat breast cancer nsclc pancreatic cancer reblozyl reblozyl luspaterceptaamt erythroid maturation agent indicate treatment anemia adult patient beta thalassemia require regular red blood cell transfusion inrebic inrebic fedratinib kinase inhibitor indicate treatment adult patient intermediate highrisk primary secondary postpolycythemia vera postessential thrombocythemia myelofibrosis empliciti empliciti elotuzumab biological product humanize monoclonal antibody treatment multiple myeloma baraclude baraclude entecavir oral antiviral agent treatment chronic hepatitis b vidaza vidaza azacitidine injection pyrimidine nucleoside analog show reverse effect deoxyribonucleic acid hypermethylation promote subsequent gene reexpression indicate treatment patient follow myelodysplastic syndrome subtype refractory anemia refractory anemia ring sideroblast accompany neutropenia thrombocytopenia require transfusion refractory anemia excess blast refractory anemia excess blast transformation cml license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence rdp exclusivity right develop country provide certain nonpatent incentive development medicine example eu japan certain country rdp exclusivity right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive provide market exclusivity period product expire patent term eu japan provide rdp period time approval new drug regulatory agency rely innovators data approve competitor generic copy certain market patent protection form market exclusivity expire rdp particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration rdp exclusivity basis competitor safety efficacy datum drug drug identical market innovator patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion impact generic competition business refer competition specific aspect law govern market exclusivity datum regulatory protection pharmaceutical vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term regulatory review period innovator depend number factor apply government restore lose patent term extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical product company file nda medicine biological product bla file type application file affect rdp exclusivity right chemical product competitor seek launch generic substitute chemical innovative drug file anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph iv certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph iv certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical study conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity medicine approve nda receive type rdp innovative chemical pharmaceutical product entitle year rdp fda approve generic substitute innovators patent challenge describe generic manufacturer file anda fourth year fiveyear rdp period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation drug new indication basis new clinical study receive year rdp formulation indication biologic product healthcare legislation enact create approval pathway biosimilar version innovative biological product previously exist prior time innovative biologic essentially unlimited regulatory exclusivity new regulatory mechanism fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar version file year approval innovator product qualify innovative biological product receive year regulatory exclusivity mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable eu extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product eu centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum maa ema ema evaluate maa provide recommendation ec ec approve deny maa possible new chemical product obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu country process place simultaneously product market eu country process complete company market new product pricing reimbursement procedure month year complete eu product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file maa product health authority maa approved generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state contrast patent eu list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general eu law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside eu japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar eu develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor follow chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur eu japan sell pharmaceutical product country datum provide country bycountry basis individual country revenue significant outside eu japan instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical study datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate generally estimate loe table pertain rdp composition matter com patent expiration respective product patent term restoration ptr grant estimate loe eui japan revlimid lenalidomidea opdivo nivolumab eliquis apixabanb orencia abataceptc pomalystimnovid pomalidomide sprycel dasatinibe yervoy ipilimumab abraxane paclitaxelf empliciti elotuzumab reblozyl luspaterceptaamtg inrebic fedratinibh product footnote information currently market product country region indicate revlimid settlement natco pharma ltd natco partners affiliates natco grant volumelimite license sell generic lenalidomide commence march settlement lotus pharmaceutical co ltd alvogen pine brook llc collectively alvogen alvogen grant volumelimite license sell generic lenalidomide begin confidential date time march addition natco alvogen grant license sell generic lenalidomide volume limitation begin january natcos alvogen ability market generic lenalidomide contingent obtain approval anda eu licenses grant party market generic lenalidomide product certain condition prior expiry patent supplementary protection certificate spc right uk begin january european country spc force begin february refer item financial statement supplementary datanote legal proceeding contingency information b eliquis refer item financial statement supplementary datanote legal proceeding contingency information c orencia eu estimate loe date base method use patent expire bms aware orencia biosimilar market eu japan formulation additional patent expire pomalyst refer item financial statement supplementary datanote legal proceeding contingency information europe japan estimate loe date base regulatory datum protection exclusivity e sprycel bms enter settlement agreement apotex inc apotex patent infringement suit cover monohydrate form dasatinib apotex launch generic dasatinib monohydrate anda product september early certain circumstance eu epo opposition division uphold validity patent direct use dasatinib treat cml expire generic enter market indication cover patent refer item financial statement supplementary datanote legal proceeding contingency information f abraxane settlement actavis llc actavis grant license certain patent require sell generic paclitaxel proteinbound particle injectable suspension product begin march eu generics enter market japan estimate loe base method use patent refer item financial statement supplementary datanote legal proceeding contingency information g reblozyl ptr application pende grant estimate loe patent h inrebic ptr application pende grant estimate loe patent estimate loe eu country base france germany italy spain uk research development rd critical longterm competitiveness concentrate rd effort follow disease area significant unmet medical need oncology include io hematology include multiple myeloma lymphoma chronic lymphocytic leukemia immunology priority relapse multiple sclerosis psoriasis lupus ra inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priority lung ipf liver nash continue analyze selectively pursue promising lead area rd pipeline include potential medicine modality include small chemically manufacture molecule large protein moleculesalso know biologicsand millamolecule antibody drug conjugate cellular therapy gene therapy addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation eu foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug typically include phase phase ii phase iii clinical study design specifically support application regulatory approval particular indication assume study successful phase clinical study involve small number healthy volunteer patient suffer indicate disease test safety proper dosing phase ii clinical study involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical study conduct confirm phase ii result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate regulatory approval typically base result phase iii clinical study times approval grant base datum early study consider registrational study significant rd program program include investigational compound phases ii iii development initial indication market product development additional indication formulation substantial component rd program strategy include expand portfolio market product hematology io opdivo combination yervoy agent secondline therapy new indication drug development time consume expensive risky rd process typically take fourteen year approximately half year spend phase iii latestage development average molecule discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately small molecule enter phase development fail achieve regulatory approval small molecule enter phase ii development failure rate approximately approximately phase iii later stage small molecule fail achieve approval biologic failure rate approximately phase development approximately phase ii development approximately phase iii later stage development total rd expense include cost discovery research preclinical development earlystage latestage clinical development drug formulation post commercialization medical support market product proportionate allocation enterprisewide cost upfront contingent milestone payment license acquire asset rd expense billion billion billion include license asset acquisition charge approximately million billion end employ approximately people rd relate support activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel manage rd program product portfolio basis invest resource stage rd early discovery latestage development continually evaluate portfolio rd asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual rd expense year opdivo individual investigational compound market product represent rd expense year operating model evolution rd geographic footprint significantly transform foster speed innovation future transformation involve closing hopewell new jersey wallingford connecticut rd site accompany additional investment expansion open example expand lawrenceville new jersey redwood city california site open new rd facility cambridge massachusetts addition acquisition celgene add rd facility strategic location europe include san diego california seattle washington cambridge massachusetts summit new jersey san francisco california supplement internal drug discovery development program acquisition alliance collaborative agreement help bring new molecular agent capability platform pipeline celgene transaction add broad earlytomid stage pipeline unique compound clinical development celgene pipeline build couple internal research development program distribute research development model focus identify support development disruptive innovative therapy outside company alliance collaboration management continue emphasize leadership innovation productivity quality strategy success rd activity list investigational compound clinical study approve potential indication market product relate therapeutic area january list compound ultimately market product depend result clinical study competitive landscape potential product market reimbursement decision payer manufacturing process necessary produce potential product commercial scale factor assurance seek regulatory approval compound approval sought obtain assurance compound get approve commercially successful stage development determine intellectual property issue patent protection available investigational compound hematology phase phase ii phase iii approve indication opdivo opdivo opdivo revlimid hematologic nonhodgkin lymphoma diffuse refractory hodgkin lymphoma l multiple myeloma malignancy large bcell lymphoma empliciti revlimid mantle cell lymphoma lisocel cd car nonhodgkin lymphoma follicular l multiple myeloma mds l mantle cell lymphoma pomalystimnovid multiple myeloma lymphoma pediatric hodgkin lymphoma relapsedrefractory multiple previously treat follicular orvacel bcma car primary testicular lymphoma myeloma lymphoma relapsedrefractory opdivo empliciti reblozyl relapsedrefractory adult multiple myeloma relapsedrefractory multiple esa nave mds cell leukemialymphoma bb bcma car myeloma mds previously treat esa opdivo idhifa inrebic advanced hodgkin relapsedrefractory l acute myeloid leukemia lymphoma mf previously treat multiple myeloma newly diagnose acute myeloid ruxolitinib pomalystimnovid relatlimab leukemia idh mutation idhifa multiple myeloma hematologic reblozyl relapsedrefractory acute myeloid relapsedrefractory multiple malignancy mf anemia leukemia idh mutation myeloma bet inhibitor nontransfusiondependent istodax empliciti nonhodgkin lymphoma betathalassemia l peripheral tcell lymphoma pomalystimnovid bet inhibitor lisocel cd car relapsedrefractory multiple lisocel cd car nonhodgkin lymphoma l diffuse large bcell myeloma relapsedrefractory aggressive relapsedrefractory lymphoma large bcell lymphoma empliciti revlimid acute myeloid leukemia l diffuse large bcell relapsedrefractory multiple idecel bcma car bcma adc lymphoma myeloma l relapsedrefractory multiple relapsedrefractory chronic lymphocytic leukemia myeloma sprycel multiple myeloma idecel bcma car l cml dnmt inhibitor cc bcma tce l relapsedrefractory multiple pediatric angioimmunoblastic tcell relapsedrefractory myeloma lymphoma refractory cml multiple myeloma l relapsedrefractory multiple low risk mds vidaza cdxcd bispecific myeloma postinduction acute myeloid acute myeloid leukemia antibody iberdomide celmod leukemia maintenance chronic myelomonocytic relapsedrefractory multiple myeloma leukemia acute myeloid leukemia dnmt inhibitor cc mds celmod post hma failure mds reblozyl relapsedrefractory transfusiondependent acute myeloid leukemia betathalassemia relapsedrefractory inrebic multiple myeloma mf relapsedrefractory nonhodgkin lymphoma idhifa relapsedrefractory aml antisirp nonhodgkin lymphoma istodax cutaneous tcell lymphoma lsd inhibitor peripheral tcell lymphoma relapsedrefractory nonhodgkin lymphoma mata lymphoma oncology approve phase phase ii phase iii indication opdivo opdivo opdivo opdivo solid tumor l crc l glioblastoma l braf wildtype opdivo yervoy ovarian l hcc metastatic melanoma solid tumor pan tumor tmb high l head neck adjuvant melanoma opdivo motolimod pediatric l head neck locally advanced melanoma braf status scchn opdivo l esophageal mesothelioma relatlimab solid tumor adjuvant bladder previously treat solid tumor opdivo yervoy adjuvant advanced rcc nlrp agonist metastatic castrationresistant esophagealgastroesophageal previously treat solid tumor prostate adjuvant gastric gastric cancer japan antitim opdivo yervoy adjuvant hcc previously treat hcc solid tumor solid tumor adjuvant melanoma previously treat sting agonist opdivo cdk inhibitor adjuvant rcc metastatic head neck solid tumor neoadjuvant erher breast metastatic castrationresistant previously treat opdivo relatlimab prostate metastatic melanoma ep antagonist solid tumor neoadjuvant erher breast previously treat solid tumor opdivo linrodostat neoadjuvant nsclc metastatic msihigh ahr crc solid tumor periadjuvant nsclc solid tumor previously treat opdivo bempegaldesleukin unresectable nsclc antictla nfprobody metastatic non solid tumor solid tumor opdivo yervoy squamous nsclc antiicos opdivo bempegaldesleukin l bladder previously treat l bladder l esophageal metastatic sclc solid tumor pomalystimnovid l gastric previously treat antitigit pediatric glioblastoma l hcc metastatic squamous solid tumor nsclc antictla nf l head neck anticd previously treat solid tumor l mesothelioma solid tumor metastatic urothelial antictla probody l nsclc bet inhibitor opdivo yervoy solid tumor adjuvant melanoma solid tumor l metastatic melanoma ccr dual antagonist adjuvant rcc antisirp l rcc solid tumor nsclc egfr mutant solid tumor braf wildtype cabiralizumab unresectable nsclc metastatic melanoma gemoab cdxpsca solid tumor opdivo relatlimab melanoma solid tumor l melanoma braf status antiil opdivo linrodostat previously treat solid tumor metastatic msihigh l metastatic melanoma lsd inhibitor crc neoadjuvant muscle invasive extensive stage sclc yervoy bladder cancer mata adjuvant melanoma opdivo bacillus calmette solid tumor guerin adolescent metastatic melanoma highrisk nonmuscle invasive bladder cancer metastatic melanoma opdivo bempegaldesleukin abraxane l melanoma breast opdivo bempegaldesleukin gastric l rcc locally advanced metastatic nsclc opdivo yervoy cabozantinib metastatic breast cancer metastatic rcc nsclc marizomib pancreatic newly diagnose glioblastoma unresectable pancreatic immunology phase phase ii phase iii approve indication tyk inhibitor branebrutinib orencia orencia autoimmune disease rheumatoid arthritis idiopathic inflammatory active polyarticular jia tlr antagonist sjgren disease myopathy early rheumatoid arthritis autoimmune disease systemic lupus nulojix jia intravenous sp agonist erythematosus switch calcineurin jia subcutaneous inhibitor renal transplant autoimmune disease tyk inhibitor psoriatic arthritis tyk inhibitor il agonist crohn disease ra auto injector psoriasis autoimmune disease lupus nephritis ra intravenous ozanimod mk psoriatic arthritis ra subcutaneous crohn disease autoimmune disease systemic lupus nulojix erythematosus relapse multiple sclerosis de novo renal transplant ulcerative colitis ulcerative colitis iberdomidecelmod systemic lupus erythematosus antiil eosinophilic esophagitis cardiovascular phase phase ii phase iii approve indication factor xia inhibitor eliquis eliquis thrombotic disorder pediatric heart disease stroke prevention atrial fibrillation fpr agonist nitroxyl donor venous thromboembolism prevention heart failure heart failure orthopedic surgery relaxin factor xia inhibitor venous thromboembolism treatment heart failure thrombotic disorder fibrotic disease phase phase ii lpa antagonist hsp pulmonary fibrosis fibrosis pegbelfermin nonalcoholic steatohepatitis jnk inhibitor idiopathic pulmonary fibrosis nonalcoholic steatohepatitis note pipeline exclude clinical collaboration development partnership opdivo yervoy relatlimab ep ono collaboration ono include early stage compound empliciti abbvie bempegaldesleukin nektar cabiralizumab prime therapeutics inc cabozantinib exelixis inc eliquis pfizer factor xia inhibitor janssen pharmaceuticals inc hsp nitto denko corporation cdxcd gemoab cdxpsca gem gemoab monoclonal gmbh bb idecel bluebird bio inc reblozyl acceleron pharma inc idhifa mata agios pharmaceuticals inc ahr ikena oncology trial explore combination partnerrun study january follow potential registrational study readout anticipate opdivoyervoy metastatic set hematology asset tumor trial time asset disease trial time empliciti opdivo cabo rcc cmer h l multiple myeloma h revlimid l chronic lymphocytic opdivo yervoy esophageal cm h transcendcll leukemia opdivo lisocel l te diffuse large bcell melanoma h transform relatlimab jcar lymphoma l tne diffuse large bcell opdivo yervoy bladder cm pilot lymphoma opdivo yervoy gastric cm idecel l multiple myeloma karmma opdivo yervoy head neck cm bb l multiple myeloma karmma opdivo yervoy mesothelioma cm opdivo melanoma renal bladder opdivo nktr opdivoyervoy early stage set immunology asset tumor trial time asset disease trial time opdivo yervoy melanoma cm h ozanimod ulcerative colitis true north mid muscleinvasive bladder poetykpso opdivo cm h h cancer moderate severe plaque m tyk psoriasis poetykpso opdivo chemo nsclc neoadjuvant cm h m opdivo esophageal cm alliance enter alliance party transfer right develop manufacture market andor sell pharmaceutical product alliance include license codevelopment cocommercial arrangement joint venture alliance involve share research development cost overall investment risk bms bms nonbms compound lead revenuegenerate product reduce profitability alliance product generally low profit alliance product share alliance partner profit sharing royalty actively pursue arrangement view alliance important complement discovery development commercialization activity alliance arrangement contain customary early termination provision follow material breach bankruptcy product safety concern arrangement typically provide termination bms cause notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination notice period generally available involuntary bankruptcy petition file dismiss material breach party occur cure bms terminate cause bms right terminate cause exercisable specify period time elapse alliance agreement sign alliance typically contain provision provide party right terminate alliance typically retain right party product intellectual property alliance terminate loss right product market sell pursuant alliance material result operation loss cash flow cause loss right material financial condition liquidity alliance agreement structure terminate specific date product patent expiration date expiry date profit sharing payment typically expiration date royalty payment cease loe include patent expiration refer item financial statement supplementary datanote alliance information significant alliance agreement alliance agreement marketing distribution customer promote appropriate use product directly healthcare professional organization doctor nurse practitioner physician assistant pharmacist technologist hospital pbms mco provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical refer government regulation field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information potential additional use product provide information scientific exchange scientific congress share information product appropriate way include development publication response unsolicited inquiry doctor medical professional mcos operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new approve product use approve use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler specialty distributor less extent directly distributor retailer hospital clinic government agency pharmacie revlimid pomalyst distribute united states primarily contract pharmacy revlimid rem pomalyst rem program respectively proprietary mandatory riskmanagement distribution program tailor specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distribute mandatory riskmanagement distribution program tailor meet local authority specification provide product safe appropriate distribution use program vary country depend country design riskmanagement program product sell hospital retail pharmacy refer item financial statement supplementary datanote revenue gross revenue large pharmaceutical wholesaler percentage global gross revenue business dsas substantially direct wholesaler distributor customer allow monitor wholesaler distributor inventory level require wholesaler distributor maintain inventory level month demand dsa include large wholesaler expire december subject certain termination provision nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report reliably gather report inventory level customer number country outside contract distributor support certain product service provide distributor vary market include distribution logistic regulatory pharmacovigilance andor sale advertising promotion competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service rd new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product revenue impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale advancement treat cancer io therapy continue evolve rapid pace io product particularly opdivo operate highly competitive marketplace addition compete market share io product approve indication lung cancer melanoma face increase competition exist compete io product receive fda approval additional indication new io agent receive fda approval enter market furthermore therapy combine different io product io product exist chemotherapy target therapy treatment investigate potential expand approval anticipate io product continue experience intense competition competitive challenge face generic pharmaceutical manufacturer eu regulatory approval process exempt generic costly timeconsuming clinical study demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far rd researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion product revenue short period time expiration exclusivity rate revenue decline product vary country general decline market rapid develop country observe rapid decline number eu country decline develop country tend rapid develop country rate revenue decline expiration exclusivity historically influence product characteristic example drug large patient population eg prescribed key primary care physician tend experience rapid decline drug specialized area medicine eg oncology drug complex manufacture eg sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity refer product intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment pricing price constraint market access medicine price base number factor include value scientific innovation patient society context overall health care spend economic factor impact health care system ability provide appropriate sustainable access necessity sustain investment innovation platform address unmet medical need central price clinical value innovation bring market current landscape alternative treatment option goal ensure appropriate patient access innovation sustain investment creative platform continue explore new pricing approach ensure patient access medicine enhance patient access medicine priority focus offer creative tiere pricing voluntary licensing reimbursement support patient assistance program optimize access protect innovation advocate sustainable healthcare policy infrastructure leverage advocacypayer input utilize partnership appropriate improve access care supportive service vulnerable patient partnership demonstration project important factor pricing medicine depend government regulation subject increase international domestic effort government implement strengthen measure regulate pharmaceutical market access product pricing payment require provide discount pricing rebate federal government respective state government purchase pharmaceutical product federal state healthcare program federal government official legislator continue face intense pressure public manage perceive high cost pharmaceutical respond pursue legislation rule reduce cost drug federal government pays monitor effort state include law recently enact california vermont nevada new york focus provide drug pricing transparency seek additional rebate limit state spend drug international federal state legislative regulatory development create new constraint ability set price andor impact market access certain area discussion pricing pressure risk refer item risk factor growth mco pbms optum uhc silver script cvs express script esi major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physicians physician organization pbms party support formulary management contracting mcos organization consolidate few large entity enhance purchasing strength importance successfully compete formulary position mcos pbms demonstrate product offer medical benefit cost advantage compare form care exclusion product formulary lead sharply reduce usage patient population consequently pharmaceutical company compete aggressively product include new product introduce compete product market product later develop competitor possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco pbm formulary note generic drug exempt costly timeconsuming clinical study demonstrate safety efficacy lower cost brandname drug mcos pbms focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid market outside operate environment governmentmandate costcontainment program market significant portion fund healthcare service determination pricing reimbursement pharmaceutical product subject direct government control point care government significant power large single payer result product face restrict access public private payer subject assessment comparative value effectiveness competitive product government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut rebate scheme method cost control eu countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing eu markets germany government set pricing restriction launch pricing freedom subsequently limit company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available patient market additionally member states eu regularly impose new additional cost containment measure pharmaceutical volume discount cost cap cost sharing increase excess prior year cost individual product aggregate market level spend outcomebase pricing scheme free product portion expect therapy period recent year italy example impose mandatory price decrease clawback rebate structure existence price differential eu different national pricing reimbursement law lead significant parallel trade flow government regulation pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act federal statute regulation state statute regulation include newly enact state law regulate drug price transparency rebate drug spending law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment fda particular importance jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market regulatory review process resource intensive undertake fda pharmaceutical manufacturer improvement efficiency process significant impact bring new therapy patient quickly fda employ tool facilitate development certain drug expedite certain application include fast track designation breakthrough therapy designation priority review accelerate approval incentive orphan drug develop rare disease example recent year fda oncology center excellence oce establish project test novel approach efficient regulatory review oncology drug realtime oncology review pilot program assessment aid assessment aid pilot program fda approve empliciti november additional multiple myeloma indication combination pomalidomide dexamethasone treatment adult patient receive prior therapy include lenalidomide proteasome inhibitor approval achieve week priority review prescription drug user fee act pdufa date develop framework concurrent review supplemental oncology application multiple approval authority oce initiate project orbis action initiative allow simultaneous decision australian therapeutic good administration tga health canada fda oncology drug fda mandate drug manufacture package label conformity cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw delay product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject pdma federal food drug cosmetic act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain safety relate drug labeling change mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical study prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize knowingly offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement administration procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy healthcare industry subject governmentimposed regulation authorize price price control continue impact total revenue participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate federal government program specify discount certain federal government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase result hr affordable care act reconciliation bill contain package change healthcare bill continue experience additional financial cost certain change business example require provide discount brandname drug patient fall medicare coverage gap refer donut hole pay annual nontaxdeductible fee federal government base allocation market share brand drug sale certain government program include medicare medicaid department veterans affairs department defense tricare annual fee impose pharmaceutical manufacturer billion activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda ec approval obtain product approval product comparable regulatory authority country outside eu case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country discussion rebate program refer item management discussion analysis financial condition result operation gtn adjustment critical accounting policy source availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source refer manufacture quality assurance discussion particular product manufacture quality assurance operate manage manufacturing network manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing refer government regulation significant biologic pharmaceutical manufacturing facility locate puerto rico ireland switzerland require significant ongoing capital investment maintenance compliance increase regulatory requirement example fda approve large scale multiproduct bulk biologic manufacturing facility deven massachusetts continue capital investment facility addition expect continue modification exist manufacturing network meet complex processing standard require grow portfolio particularly biologic cell therapy biologic manufacturing involve complex process traditional pharmaceutical operation example complete new largescale biologic manufacturing facility cruiserath ireland approve fda december eu january cellular therapy product candidate include lisocel idecel invest manufacturing network include facility bothell washington summit new jersey thirdparty manufacturer regulatory requirement product involve technically sophisticated manufacturing process require specialized raw material example manufacture clinical commercial use number sterile product biologic product car product particularly complex involve highly specialized manufacturing technology result slight deviation point production process lead production failure recall rely party manufacture supply portion active product ingredient drug substance necessary manufacture product opdivo eliquis sprycel yervoy baraclude reyataz reblozyl inrebic abraxane pomalystimnovid sustiva franchise expand use party manufacturer drug product finish good manufacturing continue shift thirdparty manufacturer supply establish brand respect revlimid thalomid operate manufacturing facility zofingen switzerland produce active product ingredient revlimid thalomid contract thirdparty manufacturer provide backup active product ingredient revlimid thalomid maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt certain supply arrangement extend multiple year commit amount expect near long term demand requirement subject change additional protection case step maintain approve backup source available example capability manufacture opdivo internally arrangement thirdparty manufacturer meet demand connection acquisition divestiture license collaboration arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party intend continue enter agreement future addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain record demonstrate quality integrity technical information production process control production process involve establish specification standard ingredient equipment facility manufacturing method operation packaging material labeling perform test stage production process final product product sample hold stability ensure product meet regulatory requirement conform standard test involve chemical physical analyse microbiological testing combination analyse quality control testing provide business unitsite thirdparty laboratory quality assurance group routinely monitor manufacturing procedure system subsidiary thirdparty supplier assure quality compliance requirement meet environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis material addition invest project reduce resource use energy water believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter refer item financial statement supplementary datanote legal proceeding contingency employee approximately employee december foreign operation significant operation outside conduct subsidiary distributor international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material sec pursuant section securities exchange act amended exchange act document available secs website wwwsecgov information relate corporate governance bristolmyer squibb include principle integrity code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website usour company leadership investor caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsshareholder service caption addition information sustainability program available website ussustainability caption forego information website content convenience information contain connected website deem incorporate reference file sec incorporate reference certain information part definitive proxy statement annual meeting shareholder proxy statement sec allow disclose important information refer manner refer information proxy statement available website investorssec filing caption day end fiscal year item risk factor risk uncertainty describe significantly negatively affect business operation financial condition operate result include component financial result cash flow prospect reputation credit rating future cause trading price common stock decline significantly additional risk uncertainty presently know risk currently consider immaterial impair business operation financial condition operate result cash flow follow discussion risk factor contain forwardlooke statement discuss item management discussion analysis financial condition result operationsspecial note forwardlooke statement encounter difficulty integrate celgene business operation fully realize project benefit acquisition celgene significant additional indebtedness incur issuance additional share connection acquisition negative consequence ultimate success acquisition celgene ability realize anticipate benefit acquisition include expect cost saving avoidance synergy innovation opportunitie operational efficiency depend thing effective integrate bristol myers squibb celgene operation product employee process integrate large number manufacture operational administrative system achieve consistency combine company include respect human capital management portfolio rationalization finance accounting system sale operation product distribution pricing system methodologie datum security system compliance program internal control process integration complex costly timeconsuming process difficulty integration operation occur adversely affect business include way cause failure meet demand product adversely affect ability meet financial reporting obligation inconsistency standard control procedure policy adversely affect ability maintain relationship customer supplier distributor alliance partner creditor clinical trial investigator manager clinical trial unable successfully combine business efficient costeffective manner anticipated timeframe project benefit cost saving realize fully long realize expect business unable grow plan materially impact business cash flow financial condition result operation adversely impact share price integration process result significant expense charge cash noncash attention certain member management resource time focus integration business company divert daytoday business operation disrupt ongoing business acquisition increase debt result additional interest expense additional cash require dividend declare additional share issue connection acquisition factor reduce financial flexibility continue capital investment develop new product declare future dividend event outside control include change regulation law economic trend adversely affect ability realize expect benefit acquisition public announcement datum clinical study competitor news development relate competitor product latestage compound cause significant volatility stock price depend datum result adverse impact business financial condition result operation development key latestage product candidate delay discontinued clinical study meet primary endpoint stock price decline significantly adverse impact business financial condition result operation focus effort resource disease area high unmet need focus portfolio investor place heighten scrutiny product latestage compound experienced setback continue development clinical study additionally inherit latestage compound prioritize brand portfolio hematology immunology acquisition celgene meet expectation announcement datum clinical study competitor news development relate competitor product late stage compound opdivo cause significant volatility stock price depend news result adverse impact business financial condition result operation furthermore announcement negative unexpected datum discontinuation development key latestage product candidate delay anticipate timeline file regulatory approval significant advancement competitor cause stock price decline significantly adverse impact business financial condition result operation assurance datum clinical study support filing regulatory approval key product candidate prove effective effective compete product approve product commercially successful approve indication increase pricing pressure restriction abroad mcos institutional purchaser government agency program continue negatively affect revenue profit margin product continue subject increase pressure portfolio market access pharmaceutical pricing control discount restriction eu region world result low price low reimbursement rate small population payer reimburse negatively impact revenue profit margin include impact increase pricing pressure medicare formulary medicare b reimbursement rate include potential implementation pilot program center medicare medicaid services cms thing set payment amount physician b drug base international drug price include percent medicare b single source drug expand utilization b drug pricing program b commercial formulary general ii rule practices mcos institutional governmental purchaser take action control cost shift cost burden manufacturer include action result exclusion product unfavorable placement product mco formulary iii government administrative policy change change law regulation federal healthcare program medicare medicaid government action inquirie federal level include proposal contain american patient blueprint seek amend pharmaceutical pricing reimbursement practice international pricing index modify federal antikickback statute discount safe harbor accelerate generic drug approval process promote use biosimilar drug option apply step therapy list price product dtc television advertisement grant additional authority governmental agency manage drug utilization negotiate drug price law state level include law recently enact california vermont nevada new york focus drug pricing transparency andor limit state spend drug include propose rule federal government allow state certain nonfederal government entity submit proposal fda allow importation certain prescription drug canada iv potential impact change federal pharmaceutical coverage reimbursement policy practice include change result implementation guidance final rule issue cms calculation average manufacturer price good price require inclusion sale territory calculation average manufacturer price good price begin april scrutiny drug manufacturer include celgene house oversight reform committee january seek document detailed information drugprice practice v reimbursement delay vi government price erosion mechanism europe country result deflation pharmaceutical product pricing vii increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary viii collection delay failure pay governmentfunde public hospital outside ix impact pricing parallel trade drug importation border x development technology andor industry practice impact reimbursement policy practice thirdparty payer xi inhibited market access real perceive difference value proposition product compare compete product expect market access constraint pharmaceutical pricing control discount restriction acute continue negatively affect future revenue profit margin additionally early health resource services administration hrsa finalize regulation b pricing methodology provide guideline civil monetary penalty issue know intentional manufacturer overcharge b cover entity effective date regulation january follow effective date manufacturer find knowingly intentionally overcharge b cover entity subject significant monetary penalty finding result negative publicity harm manufacturer reputation cause business disruption course past year celgene receive inquiry hrsa limited distribution network revlimid pomalyst thalomid compliance b program believe comply applicable legal requirement ultimately require change sale pricing practice regard distribution drug b program require pay penalty applicable regulation adverse effect revenue profitability experience difficulty delay development commercialization new product compound product appear promise development fail reach market expected optimal timeframe addition product extension additional indication approve furthermore product indication approve fda accelerated approval program contingent verification description clinical benefit confirmatory study study successful example july announce phase iii checkmate trial meet primary endpoint overall survival opdivo plus chemotherapy versus chemotherapy therapy patient firstline nonsquamous nsclc develop commercialize new compound product involve inherent risk uncertainty include efficacy safety concern delay deny regulatory approval delay challenge produce product commercial scale excessive cost manufacture product ii inability enroll patient timely completion clinical trial iii failure enter implement optimal alliance development andor commercialization new product iv failure maintain consistent scope variety promise latestage product v failure product achieve maintain commercial viability vi change regulatory approval process cause delay denial new product approval unable predict change law regulatory policy affect business occur example partial federal government shutdown halt work federal agency employee late december late january federal employee return work subsequent extended shutdown result reduction delay fda activity include respect ongoing clinical program manufacture product product candidate product approval regulatory approval delay especially common product expect rem require fda address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product negatively impact revenue earning addition certain acquire pipeline program cancel believe commercial prospect reduce recognize material noncash impairment charge program finally lose key molecule intermediary compound library natural manmade disaster act sabotage negatively impact product development cycle lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value realize market exclusivity period country market exclusivity expire generic version approve market biosimilar introduce compete product usually substantial rapid decline product revenue market exclusivity product base patent right certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain maintain patent intellectual property right limitation use loss right material country include certain eu member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file country addition patent environment unpredictable validity enforceability patent predict certainty addition manufacturer innovative drug generic drug manufacturer able design product own license patent compete result alternative technology absent relevant patent protection product datum exclusivity period expire generic alternative version approve market generic biosimilar product manufacturer group seek financial gain increasingly seek challenge patent expire face earlierthanexpecte competition product time patent cover key product likely continue subject validity enforceability challenge patent litigation postgrant review patent office proceeding example february eu patent sprycel revoke opposition division epo experience decline european revenue entry generic market refer item financial statement supplementary datanote legal proceeding contingency information case manufacturer seek regulatory approval submit clinical study datum obtain marketing approval choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation assurance particular product enjoy market exclusivity time period appear estimate disclose assume provide financial guidance addition country india allow competitor manufacture sell compete generic product negatively impact protection afford company lowerprice generic biosimilar bms biologic product compete biologic negatively impact volume price orphan exclusivity regulatory data protection revlimid multiple myeloma indication europe expire june regulatory marketing protection revlimid europe expire june notwithstanding intellectual property right revlimid major european market remain force expect generic drug company attempt market generic version revlimid european market time particular expect generic entry revlimid united kingdom begin january european country supplemental protection certificate force begin february confident strength intellectual property right possible generic drug company successfully challenge right launch generic version revlimid prior expiration intellectual property right revlimid addition congress fda take step promote development approval generic drug biosimilar biologic example december congress enact legislation intend facilitate generic company access drug sample section consolidate appropriation act provide generic biosimilar developer private right action obtain sufficient quantity drug sample reference product manufacturer order conduct testing necessary obtain approval generic biosimilar product new law potential adverse impact business certain novel approach treatment disease chimeric antigen receptor car cell therapy present significant challenge risk development novel approach treatment disease acquisition november celgene juno car cell therapy program include lisocel idecel present new challenge risk unique nature genetic modification patient cell ex vivo certain virus reengineer cell ultimately treat disease include obtain regulatory approval fda regulatory agency limit experience development cellular therapy involve genetic modification patient cell develop deploy consistent reliable process limit contamination engineering patient cell ex vivo infuse genetically modify cell patient develop process safe administration cellular therapy include longterm followup patient receive cellular therapy source additional clinical approve commercial supply material manufacture process potential car product use reengineered cell potential cancer treatment recent development broadly accept regulatory patient medical community able satisfactorily establish safety efficacy reliability therapy demonstrate potential advantage effect compare exist future therapy regulatory requirement govern gene cell therapy product change frequently continue change future furthermore certain payment model impact interest appropriate treatment site administer car cell therapy limit patient access date product involve genetic modification patient cell approve commercial sale safety profile cellular therapy adversely influence public perception adversely influence willingness subject participate clinical trial approve physician payor subscribe novel treatment approach fail overcome challenge significant adverse event report similar therapy development novel treatment approach hampered delay adversely affect future anticipate revenue andor profitability relate therapeutic program face intense competition manufacturer bms dependent market access uptake expansion market brand new product introduction new indication product extension co promotional activity alliance partner deliver future growth competition keen include lowerprice generic increasingly aggressive generic commercialization tactic ii new competitive product enter market particularly io iii low price company product real perceive superior efficacy benefit safety risk profile differentiate factor iv technological advance patent attain competitor v clinical study result product competitor product affect value proposition product vi business combination competitor major thirdparty payer vii compete interest external partnership develop bring new product market unable compete successfully competitor product marketplace material negative impact revenue earning litigation claim infringement intellectual property adversely affect future revenue operate earning certain subsidiary involve legal proceeding include patent litigation claim patent invalid unenforceable andor cover product generic drug manufacturer party seek damage andor injunctive relief compensate allege infringement patent commercial activity resolve intellectual property infringement claim costly time consuming require enter license agreement available commercially reasonable term successful claim patent intellectual property infringement subject significant damage injunction prevent manufacture sale use affect product product event material adverse effect profitability financial condition adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute ii adverse decision litigation include product liability commercial case iii antibribery regulation foreign corrupt practice act uk bribery act include compliance ongoe reporting obligation government result settlement iv recall withdrawal pharmaceutical product force closing manufacture plant v failure fulfill obligation supply contract government customer vi product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection datum privacy law regulation viii environmental health safety sustainability matter ix tax liability result assessment tax authority subject variety international law regulation currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business operating result financial condition company include new healthcare reform initiative country include additional mandatory discount fee effort focus increase transparency drug cost ii judicial governmental decision affect pricing drug reimbursement receivable payment access marketing jurisdiction iii change intellectual property law iv change accounting standard v new increase datum privacy regulation enforcement particularly eu vi emerge new global regulatory requirement report payment value transfer healthcare professional vii potential impact importation restriction legislative andor regulatory change addition healthcare industry highly regulate subject frequent substantial change anticipate continue congressional interest modify provision affordable care act particularly give recent ruling texas v azar invalidate law unconstitutional revenue generate health insurance exchange medicaid expansion affordable care act material impact change law similar recent administration action expect limited future replacement modification repeal affordable care act adversely affect business financial result particularly legislation reduce incentive employersponsored insurance coverage predict future federal state legislative administrative change relate healthcare reform affect business change tax regulation negatively impact earning subject income taxis country globally particular passage tax cut job act reduce tax rate law complex regulation interpretation issue face audit challenge apply new law negative impact provision income taxis addition future earning negatively impact change tax legislation include repeal modification tax cut job act change tax rate tax base limit phasingout eliminate deduction tax credit increase tax certain excess income intellectual property revise tax law interpretation domestic foreign jurisdiction change rule earning repatriation change tax law country thirdparty royalty represent significant percentage pretax income operate cash flow enter arrangement entitle potential royalty party outlicense intellectual property commercialization right salesbase contingent proceed relate divestiture business arrangement minimal continue involvement contribute financial success activity royalty continue represent significant percentage pretax income include royalty relate divestiture diabete business include transfer certain future royalty right pertain amylin onglyza farxiga product sale outlicense intellectual property merck patent infringement settlement pretax income generate royalty approximately billion pretax income adversely affect royalty stream decline future period failure party meet contractual regulatory obligation adversely affect business rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize copromote sell product manage certain marketing sell human resource finance business unit functional service meet contractual regulatory obligation party pose number risk perform standard legal requirement example relation outsource significant clinical development activity innovative medicine contract research organization ii produce reliable result iii perform timely manner iv maintain confidentiality proprietary information v incur significant cyberattack business disruption vi dispute arise respect ownership right technology develop partner vii disagreement cause delay termination research development commercialization product result litigation arbitration party locate market subject political social risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party meet obligation include future royalty milestone payment adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact operation result addition party violate allege violate law regulation include local pharmaceutical code foreign corrupt practice act uk bribery act eu general data protection regulation similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence failure execute business strategy adversely impact growth profitability strategy focus deliver innovative transformational medicine patient focus set disease area unable successfully execute strategy negatively impact future result operation market capitalization connection strategy process integrate celgene ability successfully integrate celgene impact result operation able achieve cost saving expect negatively impact operate margin earning result addition unable consistently maintain adequate pipeline internal rd program transaction party support future revenue growth competition pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction unable support grow market product successfully execute launch newly approve product advance latestage pipeline manage change operating model evolution manage cost effectively operate result financial condition negatively impact failure attract retain highly qualified workforce affect ability successfully develop commercialize product success largely dependent continue ability attract retain highly qualified scientific technical management workforce include people expertise clinical rd governmental regulation commercialization connection celgene acquisition integrate unique corporate culture maintain employee morale competition qualified talent biopharmaceutical field intense sure able attract retain quality talent bristolmyer squibb celgene cost materially increase failure effectively manage acquisition divestiture alliance portfolio action adversely impact future result addition business asset acquire future underperform able successfully integrate exist business occurrence number unexpected factor prevent substantially delay consummation anticipate acquisition divestiture merger acquire inlicense number asset commit reduce debt expect continue support pipeline compound product obtain licensing acquisition future revenue profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy result cost saving avoidance increase competition safety concern regulatory issue supply chain problem factor control substantial difficulty cost delay result integrate acquisition include rd manufacturing distribution sale marketing promotion information technology activity ii policy procedure process control compliance iii tax consideration acquire debt equity security consideration business development activity connection joint venture value security fluctuate depreciate value control company acquire security connection collaborative arrangement result limited ability determine management operational decision internal control compliance policy result additional financial reputational risk successful separate underperform nonstrategic asset gain loss divestiture lose operating income asset affect earning divestiture result continued financial exposure divest business guarantee financial arrangement continue supply service arrangement potential litigation follow transaction arrangement nonperformance result obligation impose material adverse effect competitive position cash flow result operation financial condition reputation particular divested otezla connection obtain regulatory approval acquisition celgene ftc determines violate consent order agree connection divestiture ftc seek civil penalty reputation adversely affect incur asset impairment charge related acquisition divestiture reduce earning value allocate certain asset substantially impair number factor control new revise accounting standard rule interpretation result change recognition income expense materially adversely affect financial result execution implementation acquisition divestiture alliance joint venture portfolio action successful adversely impact financial condition cash flow result operation substantial debt incur finance cash portion celgene acquisition consideration consider small focused early stage deal assurance able expand business development capacity pursue opportunity require obtain additional equity debt financing result increase leverage andor downgrade credit rating depend key product revenue cash flow earning derive majority revenue earning key product prioritize brand comprise approximately revenue follow acquisition celgene expect revlimid eliquis opdivo represent significant percentage revenue earning cash flow reduction revenue product adversely impact earning cash flow major product subject issue loss patent protection significant change demand formulary access change material product liability unexpected effect regulatory proceeding negative publicity supply disruption manufacturing operation thirdparty supplier significant advancement compete product incur adverse impact business financial condition result operation trading price stock experience difficulty delay disruption manufacture distribution sale product product supply relate patient access negatively impact thing product seizure recall force closing manufacture plant ii failure failure supplier comply cgmp applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay iv failure sole source single source supplier provide necessary raw material supply finish good reasonable timeframe require quality v failure thirdparty manufacturer supply bulk active finished product time vi construction regulatory approval delay new facility expansion exist facility include intended support future demand biologic product opdivo vii failure meet new emerge regulation require product track distribution channel unique identifier verify authenticity supply chain viii manufacturing distribution issue include limit manufacturing capacity change type product produce biologic physical limitation business interruption ix disruption supply chain continuity include natural disaster hurricane global disease outbreak novel coronavirus act war terrorism external factor control impact facility critical supplier addition limited experience manufacture car cell therapy process difficult expensive approach take current future competitor sure manufacturing process employ result car cell therapie safe effective ability source supply material manufacture car cell therapy develop consistent reliable manufacturing process distribution network attractive cost good impact future anticipate revenue gross profit car cell therapy addition face challenge source supply clinical approve commercial manufacture logistical shipment delay factor control prevent delay delivery product candidate patient additionally require maintain complex chain identity custody respect patient material material move manufacturing process result slight deviation point production process car cell therapie material car cell therapy result adverse patient outcome loss product regulatory remedial action adversely affect future anticipate revenue andor profitability relate car cell therapie product labeling change market product result negative impact revenue profit margin regulatory authority need change label pharmaceutical product include product market year change result additional datum postmarkete study headtohead study adverse event report study identify biomarker objective characteristic indicate particular response product therapy study postmarkete experience produce important additional information product new information add product label affect riskbenefit profile lead potential recall withdrawal decline revenue product liability claim additional information study identify portion patient population nonresponsive medicine high risk adverse reaction label change base study limit patient population study provide additional information sponsor sponsor competitor insurance company government institution mcos scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negatively impact revenue inventory return limit patient population go forward additionally certain study result especially headtohead study affect product formulary listing adversely affect revenue illegal distribution sale party counterfeit unregistered version product steal product negative impact revenue earning reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand theft inventory warehouse plant intransit properly store later sell unauthorized channel adversely impact patient safety reputation business addition diversion product authorize market channel result reduced revenue negatively affect profitability dependent information technology system infrastructure face certain risk include cybersecurity breach datum leakage rely extensively information technology system network service include internet site data host processing facility tool physical security system hardware software technical application platform manage host provide andor party vendor assist conduct business significant breakdown invasion corruption destruction interruption critical information technology system infrastructure workforce authorize access system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction confidential information store thirdparty provider system portable medium storage device experience business interruption theft confidential information reputational damage industrial espionage attack malware cyberattack compromise system infrastructure lead datum leakage internally thirdparty provider aggregate impact operation financial condition material date target event nature expect continue cybersecurity threat rapidly evolve sophistication prevalent industry invest industry appropriate protection monitor practice datum reduce risk continue monitor system ongoing basis current potential threat maintain cyber insurance insurance sufficient cover financial legal business reputational loss result interruption breach system assurance continue effort prevent breakdown breach thirdparty provider database system adversely affect business adverse change global economic political condition adversely affect profitability global economic political risk pose significant challenge company growth profitability difficult mitigate generate approximately revenue outside revenue earning cash flow expose risk strengthen dollar exposure customer credit risk europe south america market include governmentguaranteed hospital receivables market payment receive time significant operation europe include manufacture distribution result operation negatively impact member country exit eurozone monetary union eu particular exit uk eu occur january create uncertainty affect business operation uk eu impact research commercial general business operation uk eu include approval supply product addition currently uncertainty libor continue exist issue variable rate debt base libor future undertake interest rate swap contain variable element base libor discontinuation modification libor future initiative regulate reform change manner administration variable interest rate benchmark result adverse consequence return value market security instrument return link benchmark cause volatility capital market increase cost funding libor cease exist need amend certain agreement predict alternative benchmark relate term negotiate counterpartie impact say amendment disruption credit market downgrade current credit rating increase future borrowing cost impair ability access capital credit market term commercially acceptable adversely affect liquidity capital resource significantly increase cost capital finally business operation adversely affect political volatility conflict crise individual country region include terrorist activity war guarantee pay dividend repurchase stock declaration time dividend fall discretion board director board decision depend factor include financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board deem relevant reduction elimination dividend payment dividend program adversely affect stock price addition time decide buy share market adversely affect stock price increase use social medium platform present risk challenge increase use social medium communicate company news event inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information employee patient healthcare professional stakeholder addition negative inaccurate post comment social network website damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce intentional unintentional external medium channel lead information loss addition risk relate common stock holder cvr celgene cvrs subject additional risk connection acquisition celgene issue cvrs contingent value right agreement date november cvr agreement equiniti trust company trustee pursuant cvr agreement holder cvr entitle right receive cash specify set milestone achieve set forth cvr agreement addition risk relate common stock holder cvrs subject additional risk include cvrs trade low volume adverse effect resale price cvrs market price trading volume cvrs volatile milestone specify cvr agreement achieve reason time period specify payment cvrs cvrs expire value federal income tax treatment cvrs unclear cvr payment treat ordinary income require include income prior receipt cvr payment payment respect cvrs subordinate right payment certain indebtedness prohibit acquire cvrs open market transaction private transaction certain circumstance purchase cancel outstanding cvrs agree use diligent effort achieve milestone set forth cvr agreement terminate require possible action achieve goal failure achieve goal adverse effect value cvrs item b unresolved staff comment item property principal executive office locate east th street th floor new york ny lease manufacturing rd administration storage distribution facility approximately site worldwide believe manufacturing property combination thirdparty manufacturer good operating condition provide adequate production capacity current project operation believe property subject material encumbrance easement restriction detract materially value impair use operation business information manufacturing property refer item businessmanufacture quality assurance significant manufacturing rd location geographic area follow december manufacturing rd united states europe total item legal proceeding information pertain legal proceeding find item financial statement supplementary datanote legal proceeding contingency incorporate reference item safety disclosure applicable ia information executive officer list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting shareholder elect oneyear term successor elect executive officer serve discretion board director current position age employment history past year giovanni caforio md chief operating officer director company chairman board chief executive officer chief executive officer director company member leadership team present chairman board chief executive officer nadim ahme corporate vice president commercial celgene executive vice president president hematology senior vice president worldwide market celgene member leadership team executive vice presidentpresident hematologyoncology celgene present executive vice president president hematology charles bancroft chief financial officer executive vice president global services executive vice president head integration chief financial officer executive vice president global business operation member leadership team present executive vice president head integration christopher boerner phd executive vice president seattle genetics executive vice president chief commercial officer president head commercial member leadership team president head international market present executive vice president chief commercial officer adam dubow vice president assistant general counsel china japan intercon region emac senior vice president chief compliance ethic officer region member leadership team vice president associate general counsel research development present senior vice president chief compliance ethic officer joseph e eid md vice president head oncology global medical affair merck senior vice president head global medical affair head global medical member leadership team present senior vice president head global medical affairs john e elicker senior vice president public affairs investor relation executive vice president investor relation senior vice president corporate affair investor relation member leadership team present executive vice president investor relation david v elkins group vice president chief financial officer consumer consumer medicine johnson executive vice president chief financial officer johnson member leadership team worldwide vice president chief financial officer consumer product medical development corporate function johnson johnson chief financial officer celgene present executive vice president chief financial officer samit hirawat md senior vice president global program head novartis executive vice president chief medical officer global drug executive vice president head oncology development novartis development present executive vice president chief medical officer global drug development member leadership team sandra leung general counsel corporate secretary executive vice president general counsel executive vice president general counsel corporate secretary member leadership team present executive vice president general counsel kathryn metcalfe chief communication officer deloitte llp executive vice president corporate affairs chief communication officer aetna inc member leadership team chief communication officer cvs health corporation present executive vice president corporate affairs ann powell judge chief human resource officer shire pharmaceutical executive vice president chief human resource officer senior vice president global human resource member leadership team senior vice president chief human resource officer present executive vice president chief human resource officer karen santiago vice president finance global manufacturing supply senior vice president corporate controller vice president finance commercial global capability hub lead enable function finance transformation present senior vice president corporate controller louis schmukler president global product development supply executive vice president president global product senior vice president president global product development supply development supply present executive vice president president global product development supply member leadership team rupert vessey bm bch frcp dphil president research early development celgene executive vice president research early development present executive vice president research early development member leadership team paul von autenrie senior vice president enterprise service chief information officer executive vice president chief information officer senior vice president chief information officer member leadership team present executive vice president chief information officer ii item market registrant common stock stockholder matter bristolmyer squibb common stock trade new york stock exchange symbol bmy holder common stock number record holder common stock january number record holder base actual number holder register book date base information provide eq shareowner service wells fargo shareowner service transfer agent include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company equity compensation plan information information require item contain proxy statement head item vote uponitem advisory vote approve compensation name executive officersequity compensation plan information information incorporate reference performance graph follow graph compare cumulative total stockholder return common share cumulative total stockholder return company list standard poor index composite peer group major pharmaceutical company comprise abbvie amgen astrazeneca biogen gilead glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi graph assume investment december common share sp index stock peer group company include reinvestment dividend year end december stock price performance follow graph necessarily indicative future stock price performance bristolmyer squibb sp peer group unregistere sale equity security use proceed follow table summarize surrender equity security month end december total number share approximate dollar value purchase share total number average price pay publicly announce purchase period share purchaseda sharea programsb programsb dollar million share datum october november c december month end december include share repurchase publicly announce program share common stock surrender company satisfy tax withholding obligation connection vest award longterm incentive program b board director authorize repurchase billion common stock june increase authorization repurchase common stock additional billion october board director approve new stock repurchase program authorize repurchase additional billion common stock november increase authorization repurchase common stock additional billion stock repurchase program expiration date refer item financial statementsnote equity information share repurchase program c connection stock repurchase program execute accelerated share repurchase agreement asr morgan stanley co llc barclays bank plc repurchase aggregate billion common stock asr fund cash onhand november approximately million share common stock represent approximately billion aggregate repurchase price current stock price deliver company include treasury stock agreement expect settle second quarter additional share common stock deliver company certain circumstance company require cash payment elect deliver share common stock counterpartie total number share ultimately repurchase program determine final settlement base discount volumeweighte average price common stock asr period item select financial datum follow table set forth select historical consolidated financial information period indicate information read item management discussion analysis financial condition result operation consolidate financial statement relate note include include disclosure relate november acquisition celgene select historical financial information year end december derive audit consolidated financial statement relate note year financial summary amount million share datum income statement datum total revenue net earning net earningsloss attributable noncontrolle interest bms net earning common share attributable bms basic diluted weight average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable debt securitiesab total asset longterm debta equity include current noncurrent portion b prior period amount conform current period presentation item management discussion analysis financial condition result operation management discussion analysis financial condition result operation provide supplement read conjunction consolidate financial statement relate note include enhance understanding result operation financial condition cash flow comparison fiscal omit reference fiscal year end december item management discussion analysis financial condition result operation file february executive summary bristolmyers squibb company global biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease refer summary abbreviate term end term document complete celgene transaction november expect acquisition enable create lead focus biopharmaceutical company position address need patient cancer inflammatory immunologic cardiovascular fibrotic disease highvalue innovative medicine lead scientific capability commence acquisition date bms financial statement include asset liability operate result cash flow celgene refer item financial statementsnote acquisition divestiture license arrangement discussion celgene transaction receive approval new medicine additional indication formulation currently market medicine major market eu japan include multiple regulatory milestone achievement opdivo opdivoyervoy combination investigate opdivo combination yervoy anticancer agent wide array tumor type io compound clinical development continue expand field hematology lead presence inline asset revlimid pomalyst receive regulatory approval reblozyl inrebic submit regulatory application lisocel target diffuse large bcell lymphoma additionally pipeline show significant add promise hematology malignancy celmod agent multiple modality target bcell maturation antigen bcma generation cell therapy agent expand portfolio immunology near term launch opportunitie tyk inhibitor ozanimod additionally cardiovascular space eliquis global lead oral anticoagulant drug continue experience growth eliquis brand market advance factor xia inhibitor program revenue increase result high demand prioritize brand include eliquis opdivo celgene acquisition contribute billion revenue represent approximately half growth decrease gaap ep primarily taxis result otezla divestiture amortization acquire intangible asset unwind inventory fair value adjustment cost expense result celgene acquisition partially offset high revenue adjust specify item nongaap eps increase primarily result high revenue highlight follow table summarize financial information year end december dollar million share datum total revenue dilute earning share gaap nongaap nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure refer nongaap financial measure significant product pipeline approval follow summary significant approval receive product date approval ec approval combination rituximab treatment adult patient previously treat fl grade revlimid december revlimid rituximab r chemotherapyfree combination regiman approve patient fl ec conversion accelerate fda approval fda approval opdivoyervoy line metastatic march melanoma treatment base long followup datum checkmate opdivoyervoy ec approval opdivo plus lowdose yervoy previously untreated patient intermediate poorrisk january advance rcc ec approval new strength mg mg subcutaneous administration new indication orencia april orencia injection treatment moderate severe active polyarticular juvenile idiopathic arthritis pediatric patient year age old ec approval tablet powder oral suspension formulation combination chemotherapy sprycel february treatment pediatric patient newly diagnose philadelphia chromosomepositive approve japan combination pomalidomide dexamethasone multiple myeloma follow november prior therapy include lenalidomide proteasome inhibitor empliciti ec approval combination pomalidomide dexamethasone adult patient rrmm august receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression therapy fda approval treatment adult patient intermediate highrisk primary secondary post inrebica august polycythemia vera postessential thrombocythemia myelofibrosis fda approval treatment anemia adult patient beta thalassemia require regular red blood reblozyla november cell transfusion regulatory approval obtain celgene prior completion celgene transaction refer product pipeline development development market product latestage pipeline early strategy principal strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry focus biopharmaceutical company discover develop deliver transformational medicine patient face disease area believe opportunity meaningful difference oncology solid tumor hematology immunology cardiovascular fibrosis strategic priority combine company drive enterprise performance maximize value commercial portfolio ensure longterm sustainability pipeline combine internal external innovation establish new culture embed people strategy develop new medicine follow core therapeutic area oncology priority certain tumor type hematology opportunity broaden franchise potentially sustain leadership position multiple myeloma immunology priority relapse multiple sclerosis psoriasis lupus ra inflammatory bowel disease cardiovascular disease fibrotic disease priority lung liver continue advance wave innovative medicine invest significantly pipeline internally business development activity expect acquisition celgene position lead biopharmaceutical company expand oncology hematology immunology portfolio nearterm asset additional external partnership continue invest oncology portfolio pursue monotherapy combination approach advance wave early asset explore new collaboration opportunity therapeutic area focus remain focused wellresourced cancer development program seek broaden use opdivo early line therapy expand new tumor accelerate wave oncology mechanism develop treatment option refractory oncology patient hematology opportunity launch new medicine nearterm additional pipeline opportunity long term broad effort continue address unmet medical need multiple myeloma work multiple modality mechanism action cereblon modulator celmod tcell engager car tcell therapy cancer continue advance early stage portfolio immunology cardiovascular fibrotic disease strengthen partnership diverse group company academic institution new expand research activity believe differentiate internal external focus contribute advance pipeline potentially transformational medicine commercial model successful revenue prioritize brand continue grow demonstrate strong execution strategy continue drive adoption opdivo expand additional indication tumor type monotherapy combination yervoy anticancer agent eliquis continue grow leverage good class clinical profile extensive real world datum number novel oral anticoagulant total prescription globally revlimid pomalyst transform treatment multiple myeloma lead presence continue seek opportunity leverage significant medical commercial expertise address area high unmet medical need build continue success prioritize brand remain strongly commit orencia sprycel optimistic future growth nearterm opportunity reblozyl firstinclass medicine inrebic operating model transformation commercial infrastructure uniquely leverage potential growth operating model continue evolve successful focus commercial rd manufacturing resource prioritize brand market strengthen rd capability tumor biology patient selection new biomarker deliver lean administrative function streamline manufacture network reflect importance biologic current future portfolio evolution operating model focus maintain discipline approach marketing sell administrative expense enable deliver necessary strategic financial operational flexibility invest high priority opportunity portfolio continue progress integrate company commercial research development area expect realize billion synergy result cost saving avoidance integration effort general administrative manufacturing rd procurement streamline company pricing information technology infrastructure look ahead continue implement biopharma strategy drive growth prioritize brand execute product launch invest diverse innovative pipeline aid strategic business development focus prioritize market increase investment biologic manufacturing capability maintain culture continuous improvement acquisition divestiture license collaboration arrangement significant acquisition divestiture license collaboration arrangement summarize refer item financial statement supplementary datum note alliance note acquisition divestiture license arrangement information celgene bm acquire celgene integrate global biopharmaceutical company engage primarily discovery development commercialization innovative therapy treatment cancer inflammatory disease nextgeneration solution protein homeostasis immunooncology epigenetic immunology neuroinflammation primary commercial stage product include revlimid pomalystimnovid abraxane reblozyl inrebic otezla bms divest otezla amgen regulatory approval process celgene transaction upsa bms divest upsa consumer health business taisho pharmaceutical co ltd simplify realign business portfolio result operation regional revenue composition change revenue follow year end december vs dollar million change foreign exchangeb united states europe rest world othera na total revenue include royalty alliancerelate revenue product sell regional commercial organization b foreign exchange impact derive apply prior period average currency rate current period revenue revenue impact billion revlimid celgene product represent change revenue high demand eliquis average net selling price legacy bms product increase chargeback rebate discount europe revenue impact million celgene product represent change revenue high demand eliquis opdivo partially offset foreign exchange low demand establish brand average net selling price legacy bms product low charge back rebate discount rest world revenue impact million celgene product represent change revenue high demand opdivo eliquis partially offset foreign exchange low demand establish brand average net selling price legacy bms product increase chargeback rebate discount single country outside contribute total revenue gtn adjustment recognize revenue net gtn adjustment describe critical accounting policy activity end reserve balance significant category gtn adjustment follow year end december rebate chargeback medicaid return discount dollar million cash discount medicare rebate adjustment total balance january celgene acquisition provision relate sale current period prior period payment return foreign currency translation balance december reconciliation gross product sale net product sale significant category gtn adjustment follow year end december change dollar million vs gross product sale gtn adjustment chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale gtn adjustment percentage nonus gtn adjustment primarily function product sale volume regional payer channel mix contractual legislative discount rebate gtn adjustment increase high rate gross product sale high eliquis gross product sale relatively high gtn adjustment percentage result high medicare coverage gap cost share competitive pressure maintain position healthcare payer formulary allow patient continue access medical plan product revenue year end december change dollar million vs prioritize brand revlimid na na nonus na eliquis nonus opdivo nonus orencia nonu pomalystimnovid na na nonus na sprycel nonus yervoy nonus abraxane na na nonus na empliciti nonu inrebic na na nonus na year end december change dollar million vs establish brand baraclude nonus vidaza na na nonus na brandsa nonus total revenue nonus include bms celgene product revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicate treatment patient multiple myeloma revlimid single agent indicate maintenance therapy patient multiple myeloma follow autologous hematopoietic stem cell transplant eliquis apixaban oral factor xa inhibitor target stroke prevention adult patient nvaf prevention treatment vte disorder revenue increase high demand partially offset high medicare coverage gap cost share international revenue increase high demand exclude foreign exchange impact revenue increase opdivo nivolumab fully human monoclonal antibody bind pd nkt cell approve anticancer indication include bladder blood colon head neck kidney liver lung melanoma stomach continues investigate tumor type disease area revenue increase high average net selling price decline growth rate primarily small previouslytreated advanced lung cancer market increase competition opdivoyervoy combination kidney cancer expect trend continue market stabilize new indication approve launch international revenue increase high demand result approval additional indication launch europe asia exclude foreign exchange impact revenue increase orencia abatacept fusion protein indicate adult patient moderate severe active ra psa indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular jia revenue increase high demand high average net selling price exclude foreign exchange impact international revenue increase pomalystimnovid pomalidomide proprietary distinct small molecule administer orally modulate immune system biologically important target pomalystimnovid indicate patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression day completion therapy sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate revenue increase high average net selling price high demand international revenue unchanged decline generic european competition yervoy ipilimumab monoclonal antibody treatment patient unresectable metastatic melanoma revenue increase high demand high average net selling price international revenue increase high demand result approval additional indication launch primarily europe japan exclude foreign exchange impact revenue increase abraxane paclitaxel albuminbound particle injectable suspension solventfree proteinbound chemotherapy product combine paclitaxel albumin proprietary nab technology platform treat breast cancer nsclc pancreatic cancer inrebic fedratinib oral kinase inhibitor activity wild type mutationally activate jak flt august fda approve inrebic treatment adult patient intermediate highrisk primary secondary postpolycythemia vera postessential thrombocythemia myelofibrosis reblozyl luspaterceptaamt erythroid maturation agent indicate treatment anemia adult patient beta thalassemia require regular red blood cell transfusion november fda approve reblozyl treatment anemia adult patient beta thalassemia require rbc transfusion baraclude entecavir oral antiviral agent treatment chronic hepatitis b international revenue decrease low demand result increase generic competition vidaza azacitidine injection pyrimidine nucleoside analog show reverse effect deoxyribonucleic acid hypermethylation promote subsequent gene reexpression indicate treatment patient follow myelodysplastic syndrome subtype refractory anemia refractory anemia ring sideroblast accompany neutropenia thrombocytopenia require transfusion refractory anemia excess blast refractory anemia excess blast transformation cml brand include brand include lose exclusivity major market otc brand royalty revenue international revenue decrease primarily divestiture upsa business certain brand continue generic erosion estimate endus demand pursuant sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject de minimis exception estimate level inventory distribution channel excess month hand follow product material result operation date indicate international product estimate level inventory distribution channel excess month hand september perfalgan analgesic product month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily gulf country inventory build mitigate risk product supply disruption market result sale anagni manufacture plant catalent inc december generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process revlimid pomalyst distribute primarily contract pharmacy revlimid rem pomalyst rem program respectively proprietary riskmanagement distribution program tailor specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distribute mandatory riskmanagement distribution program tailor meet local authority specification provide product safe appropriate distribution use program vary country depend country design riskmanagement program product sell hospital retail pharmacy abraxane inrebic vidaza distribute wholesaler channel direct customer distribution channel outside nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report influence demand information exist available develop variety methodology estimate datum include historical sale direct customer thirdparty market research datum relate prescription trend endus demand give difficulty inherent estimate thirdparty demand information evaluate methodology estimate direct customer product level inventory calculate month hand ongoing basis change necessary factor affect estimate include generic competition seasonality product price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior filing disclose product level inventory excess month hand expect demand subject de minimis exception quarterly report form q expense year end december change dollar million vs cost product solda marketing sell administrative research development amortization acquire intangible asset incomeexpense net total expense excess exclude amortization acquire intangible asset cost product sell cost product sell include material internal labor overhead cost own manufacturing site thirdparty product supply cost supply chain cost manage global manufacturing supply organization cost product sell include royalty profit share certain excise taxis foreign currency hedge settlement gain loss cost product sell typically vary period result product mix volume particularly royaltie profit share less extent change foreign currency price inflation cost attribute manufacturing site exit cost product sell exclude amortization acquire intangible asset cost product sell increase billion high royalty profit share million primarily high eliquis sale unwind inventory fair value adjustment million impairment charge million manufacturing packaging facility high product sale marketing sell administrative marketing sell administrative expense primarily include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost advertising product promotion cost expense manage regional commercialization organization global enable function finance legal information technology human resource certain expense share alliance partner base contractual agreement marketing sell administrative expense increase million primarily celgene expense approximately million partially offset foreign exchange impact research development research development activity include discovery research preclinical clinical development drug formulation medical support market product expense include salary benefit cost thirdparty grant fee pay clinical research organization supply upfront contingent milestone payment license asset acquisition investigational compound iprd impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost certain expense share alliance partner base contractual agreement expense typically vary period number reason include time license asset acquisition charge iprd impairment charge research development expense decrease million billion nektar relate charge partially offset celgene expense approximately million high investment io immunology development program significant charge include rd expense follow year end december dollar million license asset acquisition charge iprd impairment employee compensation charge site exit cost research development significant charge license asset acquisition charge result strategic transaction acquire license certain investigational compound option acquire license disclose acquisition divestiture license collaboration arrangement significant charge include upfront charge billion relate nektar million milestone cormorant pharmaceutical million milestone ifm therapeutics inc iprd impairment charge include discontinue development investigational compound previously acquire medarex employee compensation charge result impact retention signon arrangement connection celgene transaction site exit cost include million result expect exit rd site million charge result purchase priority review voucher expect ongoing development program amortization acquire intangible asset amortization intangible asset acquire result business combination amortization acquire intangible asset increase billion result market product right acquire celgene transaction incomeexpense net incomeexpense net change billion primarily billion cost expense result celgene transaction billion pension settlement charge partially offset billion gain sale upsa business equity investment fair value adjustment component incomeexpense net follow year end december dollar million interest expense pension postretirement royalty licensing income divestiture gain acquisition expense contingent value right investment income integration expense provision restructure equity investment gainslosse litigation settlement transition service fee intangible asset impairment equity net lossincome affiliate incomeexpense net interest expense include interest incur approximately billion note issue include million incur prior celgene acquisition date approximately billion celgene debt acquire exchange offer interest expense reduce million amortization purchase price adjustment attribute celgene debt pension postretirement include pension settlement charge include billion primarily relate termination bristolmyer squibb retirement income plan royalty license income primarily include diabete royalty million million keytruda royalty million million addition erbitux royalty million million fee amend royalty rate million salesbase milestone include divestiture gain result divestiture upsa business multiple mature global product line acquisition expense include follow item relate celgene transaction upfront bridge facility commitment term loan debt exchange fee million acquisition financing hedge loss million financial advisory legal proxy filing transaction cost million contingent value right include fair value adjustment result change trade price security investment income include million interest income earn net proceed new note issue prior celgene transaction net proceed fund portion celgene acquisition cash consideration pay relate fee expense integration expense include consulting fee incur connection celgene integration activity restructuring charge include exit cost primarily relate employee termination benefit contract termination restructuring charge relate prior company transformation initiative million million restructuring charge relate celgene transaction million include million accelerate vest celgene equity award refer item financial statement supplementary datanote restructure information equity investment gainslosse include fair value adjustment relate equity investment uniqure nv nektar equity investment obtain celgene transaction addition million relate termination europe asia partnership sanofi litigation settlement include million relate government pricing matter million relate intellectual property product liability settlement intangible asset impairment include million outlicense asset obtain acquisition zymogenetics inc meet primary endpoint phase ii clinical study equity net lossincome affiliate primarily relate partnership sanofi europe asia terminate investment limit partnership income taxis year end december dollar million earning income taxis provision income taxis effective tax rate impact specify item effective tax rate exclude specify item tax impact attribute specify item include otezla divestiture certain nondeductible expense purchase price adjustment increase effective tax rate taxis attribute internal cash repatriation low state taxis swiss tax reform adjustment finalization tax return account reduction effective income tax rate compare prior period tax reserve release lapse statute million million refer item financial statement supplementary datanote income taxis information nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item evaluate individual basis item adjust consider quantitative qualitative aspect typically follow characteristic highly variable difficult project unusual nature significant result particular period indicative future operating result similar charge gain recognize prior period likely reoccur future period include amortization acquire intangible asset begin fourth quarter include product right generate significant portion ongoing revenue recur intangible asset fully amortize unwind inventory fair value adjustment acquisition integration expense restructuring cost accelerate depreciation impairment property plant equipment intangible asset rd charge income result upfront contingent milestone payment connection acquisition licensing thirdparty intellectual property right cost acquire priority review voucher divestiture gain loss stock compensation result accelerate vest celgene award certain retentionrelate compensation charge relate celgene transaction pension legal contractual settlement charge interest expense note issue prior celgene transaction interest income earn net proceed note amortization fair value adjustment debt acquire celgene exchange offer item defer current income taxis attribute item adjust consider individual impact overall tax expense deductibility jurisdictional tax rate certain significant tax item exclude impact tax reform provide international revenue priority product exclude impact foreign exchange reconciliation nongaap measure comparable gaap measure include exhibit form k file february incorporate reference nongaap information intend portray result baseline performance supplement enhance management analyst investor overall understanding underlie financial performance facilitate comparison current past future period example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap comparable similarly title measure present company possible difference method item adjust encourage investor review financial statement publiclyfile report entirety rely single financial measure amortization acquire intangible asset previously include nongaap earning eps information amount significant financial result subsequent celgene acquisition result exclude nongaap result well reflect core operating performance comparable prior period nongaap result revise include adjustment relate amount insignificant million specify item follow year end december dollar million inventory purchase price accounting adjustment employee compensation charge site exit cost cost product sell employee compensation charge site exit cost marketing sell administrative license asset acquisition charge iprd impairment employee compensation charge site exit cost research development amortization acquire intangible asset interest expense pension postretirement royalty licensing income divestiture gain acquisition expense contingent value right investment income integration expense provision restructure equity investment gainslosse litigation settlement intangible asset impairment incomeexpense net increase pretax income income taxis item income taxis attribute otezla divestiture income taxis attribute tax reform income taxis increase net earning reconciliation gaap nongaap follow year end december dollar million share datum net earning attributable bms diluted eps calculation gaap specify item net earning attributable bms diluted eps calculation nongaap weight average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap financial position liquidity capital resource net debtcash position follow december dollar million cash cash equivalent marketable debt security current marketable debt security noncurrent total cash cash equivalent marketable debt security shortterm debt obligation longterm debt net debtcash positiona prior period amount conform current period presentation cash cash equivalent marketable security hold approximately billion december expect flexibility access cash future cash generate foreign subsidiary believe exist cash cash equivalent marketable security cash generate operation require issuance commercial paper support credit facility sufficient satisfy anticipate cash need year include dividend capital expenditure milestone payment contingent value right work capital restructuring initiation business development deem repatriation transition tax billion debt mature management continuously evaluate capital structure ensure company finance efficiently result repurchase common stock debt security termination interest rate swap contract prior maturity issuance debt security purchase cvrs issue connection celgene transaction repurchase million share common stock billion include million share billion accelerated share repurchase program announce november board director approve increase billion share repurchase authorization company common stock february increase total outstanding share repurchase authorization give effect billion share repurchase approximately billion dividend payment billion billion dividend decision quarterly basis board director annual capital expenditure approximately million billion billion expect approximately million billion continue expand biologic manufacturing capability facilityrelate activity example construct new largescale biologic manufacturing facility ireland approve fda december eu january facility expect produce multiple therapy grow biologic portfolio investment portfolio include noncurrent marketable security subject change fair value result interest rate fluctuation market factor investment policy establishe limit time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard refer item financial statement supplementary datanote financial instrument fair value measurement information commercial paper program issue maximum billion unsecured note maturity day date issuance commercial paper borrowing outstanding december december revolve credit facility total billion consist day billion facility expire january billion facility expire january fiveyear billion facility extend september july respectively facility provide customary term condition financial covenant provide backup liquidity commercial paper borrowing billion facility billion revolving facility extendable annually year anniversary date consent lender day billion facility renew year anniversary date subject certain term condition borrowing outstanding revolve credit facility december issue aggregate principal approximately billion float rate fix rate unsecured senior note maturity range month year connection celgene transaction acquire approximately billion celgene debt exchange offer economic market factor additional regulation pass future include additional healthcare reform initiative change tax law additional pricing law potential importation restriction reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer believe economic condition material impact liquidity cash flow financial flexibility uk depart eu january departure begin transition period set end december uk eu negotiate future relationship similar company industry certain regulatory trade labor aspect business likely affect transition period time currently believe matter relate financial effect material impact consolidate result operation financial position liquidity sale uk represent total revenue global health emergency concern spread novel coronavirus currently unknown aware material impact operation continue monitor situation closely include supply commercial clinical medicine region credit rating november moody sp complete rating review acquisition celgene conclude company credit rating remain unchanged bms current longterm shortterm credit rating assign moody investor service confirm prime respectively negative longterm credit outlook bms current longterm shortterm credit rating assign standard poor confirm respectively longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment credit rating downgrade affect interest rate debt incur fair market value exist debt ability access capital market generally cash flow follow discussion cash flow activity year end december dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt disbursement activity invest financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee customer discount rebate tax payment ordinary course business example annual employee bonus typically pay quarter subsequent year addition cash collection continue impact long payment term certain biologic product primarily new oncology product include opdivo yervoy empliciti day day long payment term closely align insurance reimbursement time physician cancer center follow administration patient billion change cash flow operating activity compare primarily attributable high cash collection time payment ordinary course business approximately billion include approximately billion relate celgene low rd licensing collaboration payment approximately billion primarily nektar transaction partially offset high income tax payment approximately million celgene acquisition integration relate payment approximately billion investing activity cash requirement invest activity include cash acquisition manufacturing facilityrelate capital expenditure purchase marketable security original maturity great day time purchase reduce proceed business divestiture include royalty sale maturity marketable security billion change cash flow investing activity compare primarily attributable high net acquisition payment approximately billion primarily acquisition celgene partially offset high business divestiture proceed approximately billion primarily divestiture otezla upsa consumer health business financing activitie cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing reduce proceed exercise stock option issuance longterm debt borrowing billion change cash flow financing activity compare primarily attributable high net borrowing activity approximately billion primarily result issuance new note connection acquisition celgene partially offset accelerate stock repurchase cash payment billion contractual obligation offbalance sheet arrangement payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb deem repatriation transition tax totalc include estimate future interest payment periodic cash settlement derivative b include shortterm uncertain tax benefit uncertainty timing resolution c exclude noncurrent liability uncertainty timing resolution commit aggregate billion potential future research development milestone payment party inlicense asset acquisition development program include earlystage milestone billion milestone achieve phase iii clinical study latestage milestone billion milestone achieve post phase iii clinical study payment generally payable achievement certain developmental regulatory milestone specific timing predict certain agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation refer item financial statement supplementary datanote alliance information alliance contingent value right issue connection celgene acquisition right measure fair value payment contingent achievement future regulatory milestone cvr right entitle shareholder receive onetime potential payment cash fda approval follow milestone ozanimod december lisocel jcar december idecel bb march payment milestone achieve cvrs expire maximum potential payment cvrs approximately billion payable late business day date milestone achieve offbalance sheet arrangement material reasonably likely material financial condition result operation sec consent order fcpa settlement previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form q period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec b establish business risk disclosure group c retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand e ensure budget process give appropriate weight input come adequately document process establish companywide policy concern sale direct customer purpose comply consent include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain dsas pharmaceutical wholesaler account nearly gross revenue current term dsas wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard recently issue accounting standard refer item financial statement supplementary datanote accounting policy recently issue accounting standard critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly affect financial condition result operation require difficult subjective complex judgment need estimate effect matter inherently uncertain uncertainty actual result vary estimate revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize follow step model identify customer contract identify contract performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied revenue reduce gtn sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix eg medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience follow category gtn adjustment involve significant estimate judgment information obtain external source refer item financial statement supplementary datanote revenue discussion analysis significant category gtn sale adjustment chargeback cash discount business participate program government entity significant department defense department veteran affair party include cover entity b drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag medicaid medicare rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit pay point service discount cms medicare beneficiarie coverage gap donut hole estimate unpaid unbilled rebate discount present liability rebate return discount adjustment gtn sale adjustment include sale return program base applicable law regulation individual nonus country rebate offer manage healthcare organization less extent nonus program include different pricing scheme cost cap volume discount outcomebase pricing scheme pricing clawback base sale individual company aggregation company participate specific market estimate unpaid unbilled rebate discount present liability estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loe estimate return new product determine consider historical sale return experience similar product product line similar therapeutic area andor similar distribution model estimate level inventory distribution channel project demand estimate product return present liability use information external source information external source estimate gtn adjustment estimate inventory wholesaler base project prescription demand base sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information longlive asset intangible asset valuation significant purchase price celgene acquisition allocate intangible asset include commercially market product iprd asset intangible asset billion december billion december identifiable intangible asset measure respective fair value acquisition date engage independent thirdparty valuation firm assist determine fair value asset acquisition date fair value asset estimate discount cash flow model model require use follow significant estimate assumption identification product candidate sufficient substance require separate recognition estimate revenue operate profit relate commercial product product candidate eligible patient price market share estimate future revenue probability success unapproved product candidate additional indication commercial product resource require complete development approval product candidate time regulatory approval exclusivity appropriate discount rate product market participant income tax rate allocation expect synergies product believe estimate preliminary fair value assign intangible asset acquire reasonable estimate assumption consider fact circumstance acquisition date impairment amortization longlive asset include intangible asset longlive asset include intangible asset property plant equipment review impairment event change circumstance indicate carry asset recoverable annually iprd intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loe pricing reduction adverse regulatory change clinical study result delay failure obtain regulatory approval initial follow indication unanticipate development cost inability achieve expect synergy result cost saving avoidance high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation carrying value longlive asset exceed fair value asset writtendown fair value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use estimate useful life longlive asset subjective require significant judgment patent life future plan external market factor longlive asset periodically review change fact circumstance result reduction estimate useful life asset require acceleration depreciation goodwill goodwill represent excess consideration transfer estimate fair value net asset acquire business combination goodwill billion billion december respectively assess goodwill balance single reporting unit annually event change circumstance indicate carry value goodwill recoverable determine impairment asset exist extent impairment goodwill review impairment assess qualitative factor include compare market capitalization carry value asset event circumstance require interim evaluation include unexpected adverse business condition economic factor unanticipate technological change competitive activity act government court asset heldforsale follow criterion consider concluding asset classify heldforsale management commitment plan sell availability immediate sale present condition initiation active program identify buyer probability complete sale year actively market sale reasonable price relation current fair value likelihood significant change plan plan withdraw criterion meet balance sheet date asset liability present separately balance sheet heldforsale low carrying fair value cost sell long depreciate amortize classified heldforsale income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance billion billion december net valuation allowance billion federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life discuss fully item financial statement supplementary datanote income taxis provisional tax charge billion attributable onetime deem repatriation transition tax certain foreign earning recognize fourth quarter accounting reduction defer tax asset tax rate complete december tax charge deem repatriation transition tax complete december provisional tax charge deem repatriation transition tax reduce million prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own ii conversion mead johnson class b share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class b share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code internal revenue service assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion initial public offering create restructure facilitate ipo mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis refer item financial statement supplementary datanote accounting policy recently issue accounting standardsincome taxis note income taxis contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency refer item financial statement supplementary datanote accounting policy recently issue accounting standardscontingencie note income taxis note legal proceeding contingency product pipeline development rd program manage portfolio basis early discovery latestage development include balance earlystage latestage program support future growth late stage rd program phase iii development include investigational compound initial indication additional indication formulation market product spending program represent approximately annual rd expense year opdivo investigational compound market product represent great rd expense year latestage development program potentially impact revenue earning year regulatory approval obtain product successfully commercialize follow development market product latestage pipeline product indication date development announce ec approval new indication revlimid combination rituximab anticd antibody revlimid fl december treatment adult patient previously treat fl grade combination revlimid rituximab r chemotherapyfree combination regiman approve patient fl ec announce finding naxos evaluation apixaban stroke systemic embolism prevention patient nonvalvular atrial fibrillation reallife set france large realworld datum analysis oac september effectiveness safety europe patient nvaf analysis eliquis use associate low rate major bleeding compare vitamin k antagonist rivaroxaban dabigatran datum feature nvafac latebreake oral presentation european society cardiology congress paris france announce result phase iv augustus trial evaluate eliquis versus vitamin k antagonist vkas patient nvaf acs andor undergo pci result patient receive py inhibitor march aspirin antiplatelet therapy proportion patient major clinically relevant nonmajor bleed month significantly lower treat eliquis compare treat vka announce result retrospective realworld datum analysis report outcome safety effectiveness eliquis eliquis compare low molecular weight heparin lmwh warfarin treatment vte patient active cancer realworld data analyse highlight oral presentation american society hematology annual meeting orlando florida result primary analysis show eliquis use vte december associate low rate major bleed clinicallyrelevant nonmajor crnm bleed recurrent vte compare lmwh eliquis associate low rate recurrent vte similar rate major bleeding crnm bleed compare warfarin outcome define base diagnosis code set care bmspfizer alliance announce initiation new randomize control study guardaf determine early detection atrial fibrillation screen previously undiagnose man woman year atrial fibrillation november age ultimately impact rate stroke compare usual standard medical care study assess potential bleeding lead hospitalization provide evaluation net clinical benefit harm product indication date developments ono alliance partner opdivo japan announce submission supplemental application opdivo japan additional indication msih unresectable advanced recurrent crc progress follow chemotherapy partial change approve item manufacture marketing approval mainly crc march base result phase ii checkmate study evaluate opdivo patient msih dmmr recurrent metastatic crc progress intolerant previous line treatment chemotherapy include fluoropyrimidine anticancer drug announce result phase iii attraction trial evaluate opdivo versus chemotherapy treatment patient unresectable advanced recurrent escc refractory intolerant combination therapy fluoropyrimidine platinumbase drug primary endpoint overall survival opdivo demonstrate september statistically significant improvement chemotherapy reduction risk death month escc improvement median overall survival compare patient treat chemotherapy safety profile opdivo trial consistent previously report study escc solid tumor ono alliance partner opdivo japan announce submission supplemental application opdivo indication unresectable advanced recurrent esophageal cancer japan partial change approve item manufacture marketing approval announce phase iii checkmate trial evaluate addition opdivo current standard care temozolomide radiation therapy versus standard care meet primary endpoint september progressionfree survival patient newly diagnose gbm mgmtmethylate datum monitor committee recommend trial continue plan allow primary endpoint overall survival gbm mature company remain blinded study datum announce phase iii checkmate trial evaluate opdivo plus radiation versus temozolomide plus radiation patient newly diagnose mgmtunmethylate gbm meet primary endpoint overall survival final analysis announce topline result checkmate randomize phase iii study evaluate opdivo versus sorafenib hcc june firstline treatment patient unresectable hcc trial achieve statistical significance primary endpoint overall survival prespecified analysis opdivo announce ec approval opdivo flat dose schedule mg infuse minute week october mg infuse minute week adjuvant treatment adult patient melanoma involvement lymph nodes metastatic disease undergone complete resection announce result threeyear analysis efficacy datum phase iii checkmate study evaluate adjuvant use opdivo mgkg versus yervoy mgkg patient stage iii stage iv melanoma september high risk recurrence follow complete surgical resection year followup opdivo continue demonstrate superior recurrencefree survival compare yervoy active control recurrencefree survival melanoma rate respectively announce alliance partner nektar fda grant breakthrough therapy designation investigational agent bempegaldesleukin nktr combination opdivo treatment patient previously untreate unresectable metastatic melanoma breakthrough therapy designation base august clinical datum recently report american society clinical oncology annual meeting cohort patient metastatic melanoma treat doublet therapy ongoing pivot phase iii clinical study announce longterm pool efficacy safety result phase iii checkmate checkmate study patient previously treat advanced nsclc year patient treat opdivo continue september experience longterm overall survival os benefit versus docetaxel os rate year opdivo docetaxel os benefit opdivotreate patient observe subgroup nsclc announce result pool analysis survival datum study checkmate patient previouslytreate advanced nsclc treat opdivo pool analysis april study opdivotreate patient alive year notably patient pdl greater equal fouryear overall survival rate respectively receive approval china opdivo monotherapy treatment patient scchn disease september progression platinumbase therapy tumor pdl positive expression define scchn tumor cell express pdl january acceptance china sbla filing patient previously treat metastatic recurrent scchn product indication date development announce fda accept sbla grant breakthrough therapy designation opdivo november combination yervoy treatment patient advance hcc previously treat sorafenib fda grant application priority review pdufa goal date march hcc announce result opdivoyervoy cohort phase iii checkmate study evaluate io combination patient advance hcc previously treat sorafenib minimum followup june month blind independent central review objective response rate response evaluation criterion solid tumor version time datum cutoff median duration response month announce result interim analysis phase ii checkmate trial evaluate opdivoyervoy patient mcrpc show asymptomatic minimally symptomatic patient disease progress secondgeneration hormone therapy receive chemotherapy cohort mcrpc february median followup month objective response rate additionally patient disease progress taxanebase chemotherapy cohort median followup month objective response rate announce result coprimary endpoint checkmate randomize phase iii study evaluate opdivoyervoy versus opdivo adjuvant treatment patient complete surgical removal stage iiibcd stage iv evidence disease melanoma statistically significant benefit november reach coprimary endpoint recurrencefree survival rfs patient tumor express pd l datum monitor committee recommend study continue unchanged study remain doubleblinde continue assess coprimary endpoint rfs allcomer intenttotreat population announce fiveyear result phase iii checkmate clinical trial continue demonstrate improve overall survival firstline combination opdivoyervoy versus yervoy patient september advanced metastatic melanoma minimum followup month year fiveyear overall survival rate opdivoyervoy combination opdivo yervoy announce fiveyear analysis phase study long followup opdivoyervoy combination patient previously treat untreated advanced melanoma date june melanoma analysis show median followup month range patient year long overall survival rate stable opdivoyervoy announce analysis explore longterm quality life qol symptom burden phase iii checkmate study find qol maintain treatmentfree interval period patient june study treatment free subsequent therapy patient previously untreate unresectable metastatic melanoma follow discontinuation therapy opdivo opdivoyervoy receive fda approval opdivo combination yervoy treatment patient unresectable metastatic melanoma base additional long term efficacy datum checkmate year overall survival restriction patient population approval fulfill post marketing requirement verify describe clinical benefit convert prior accelerate approval approval nivolumab combination march ipilimumab patient unresectable metastatic melanoma nivolumab monotherapy braf mutant subject unresectable metastatic melanoma importantly base fda review checkmate year overall survival datum result exploratory analysis pdl tumor expression remove entirely label announce voluntary withdrawal company application eu combination opdivo yervoy treatment advanced nsclc base datum checkmate application originally file patient firstline nsclc tumor mutational burden mutationsmegabase base final analysis progressionfree survival coprimary endpoint trial application subsequently amend include statistically significant result overall survival coprimary endpoint checkmate evaluate opdivoyervoy versus chemotherapy patient tumor express pdl january committee medicinal product human use chmp acknowledge integrity patient nsclc level datum chmp determined assessment application possible follow multiple protocol change company response rapidly evolve science datum company plan refile application eu announce fda accept sbla opdivo combination yervoy firstline treatment patient metastatic recurrent nsclc egfr alk genomic tumor aberration application base datum phase checkmate trial evaluate opdivo plus yervoy versus chemotherapy january patient previously untreate nsclc dual immunotherapy combination demonstrate significant improvement overall survival versus chemotherapy fda grant application priority review pdufa goal date product indication date development announce result phase iii checkmatela trial evaluate opdivo plus lowdose yervoy give concomitantly cycle chemotherapy firstline treatment patient advance nsclc meet primary endpoint superior overall survival prespecifie interim analysis comparator study chemotherapy october cycle follow optional maintenance therapy safety profile opdivo plus lowdose yervoy cycle chemotherapy checkmatela reflective know safety profile immunotherapy chemotherapy component firstline nsclc announce result phase iii checkmate trial evaluate opdivo plus lowdose yervoy line treatment patient advance nsclc opdivo plus lowdose yervoy meet independent coprimary endpoint overall survival demonstrate superior benefit compare chemotherapy patient tumor express pdl additionally exploratory analysis result showed improve overall survival september patient treat combination opdivo plus lowdose yervoy pdl twoyear survival rate nsclc patient treat combination regimen patient tumor express pdl patient tumor express pdl chemotherapy control arm twoyear survival rate respectively announce phase iii checkmate study evaluate opdivo plus chemotherapy versus opdivoyervoy july chemotherapy meet primary endpoint overall survival firstline nonsquamous nsclc patient regardless pdl status announce voluntary withdrawal company sbla opdivo plus lowdose yervoy treatment firstline advanced nsclc patient tmb great equal mutation megabase datum checkmate discussion fda company believe evidence relationship january tmb pdl require fully evaluate impact opdivo plus yervoy overall survival line nsclc patient analysis require availability final datum checkmate provide time review cycle current application announce new result phase iii checkmate study show therapy opdivo plus lowdose february yervoy continue demonstrate longterm survival benefit patient previously untreate advanced rcc metastatic rcc announce ec approval opdivo plus lowdose yervoy previously untreated patient intermediate january poorrisk advanced rcc announce topline result phase ii checkmate trial evaluate opdivo versus opdivoyervoy scchn april patient recurrent metastatic scchn study meet primary endpoint announce fda grant breakthrough therapy designation orencia prevention moderate severe acute gvhd hematopoietic stem cell transplant unrelated donor approve therapy gvhd december prevention acute gvhd potentially lifethreatene medical complication impact patient receive transplant treatment certain genetic disease hematologic cancer receive ec notification adoption approval orencia solution subcutaneous injection jia april prefille syringe extension application mg mg strength extension indication treatment polyarticular jia pediatric patient year age old announce datum phase iv mechanistic study explore difference cellular molecular mechanism orencia treatment adalimumab interfere disease progression moderatetosevere early ra orencia patient seropositive certain autoantibody adult patient early moderatetosevere ra june treat biologic medication test positive autoantibody call anticitrullinate protein antibody rheumatoid factor numerically high efficacy response see orencia week result prospective analysis early ample headtohead trial feature latebreake ra oral presentation annual european congress rheumatology announce submission supplemental application orencia intravenous infusion mg orencia mg syringe subcutaneous injection ml orencia mg autoinjector subcutaneous march injection ml include description inhibition structural damage joint currently approve indication ra partial change approve item manufacture marketing approval japan announce ec approval sprycel tablet powder oral suspension formulation combination sprycel february chemotherapy treatment pediatric patient newly diagnose philadelphia chromosomepositive product indication date development announce sjnda empliciti combination pomalidomide dexamethasone epd approve japan ministry health labour welfare approval base global phase ii trial eloquent november epd treatment patient mm receive prior therapy include lenalidomide proteasome inhibitor announce ec approve empliciti plus pomalidomide lowdose dexamethasone epd august treatment adult patient rrmm receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression therapy announce update datum eloquent international randomize phase ii study evaluate empliciti plus pomalidomide dexamethasone epd versus pomalidomide dexamethasone pd patient empliciti multiple myeloma rrmm nonprespecifie analysis conduct provide descriptive assessment overall survival june extend followup month patient treat epd continue experience sustain clinically relevant overall survival progressionfree survival benefit compare patient treat pd datum present th congress european hematology association poster display complete file supplemental japanese new drug application sjnda empliciti combination pomalidomide dexamethasone treatment patient multiple myeloma receive february prior therapy include revlimid proteasome inhibitor sjnda filing submit base result global phase ii study orphan designation grant indication rrmm initial jnda sjnda review priority review announce follow latecycle review meeting december bms acceleron pharma inc notify fda reblozyl review oncology drug advisory committee odac meeting schedule december agency inform bms original prescription drug user reblozyl mds december fee act target action date april sbla reblozyl remain requirement odac review bms seek approval rebloyzl erythroid maturation agent represent new class therapy treatment adult patient low intermediaterisk mdsassociated anemia ring sideroblast require red blood cell transfusion announce fda accept priority review bla lisocabtagene maraleucel lisocel company autologous anticd car tcell immunotherapy define composition purify cd cd car cell treatment adult patient relapse refractory large bcell lymphoma prior therapy fda set prescription drug user fee act goal date august lisocel lymphoma february lisocel grant breakthrough therapy regenerative medicine advanced therapy designation fda relapsedrefractory aggressive large bcell nonhodgkin lymphoma include diffuse large bcell lymphoma dlbcl specify de novo transform indolent lymphoma primary mediastinal bcell lymphoma grade b follicular lymphoma priority medicine scheme ema relapsedrefractory dlbc special note forwardlooke statement include document incorporate reference write oral statement time time contain certain forward look statement meaning section security act amend section e exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base historical performance current expectation projection future financial result goal plan objective involve inherent risk assumption uncertainty include internal external factor delay divert change year cause future financial result goal plan objective differ materially express imply statement statement likely relate thing goal plan objective financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product ability realize project benefit acquisition celgene successfully integrate celgene operation outcome contingency legal proceeding financial result forwardlooke statement guarantee include important factor cautionary statement include particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date additional risk currently deem immaterial presently know cause forwardlooke event discuss occur require federal security law undertake obligation release publicly update revision forwardlooke statement result new information future event change circumstance date item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen foreign currency forward contract manage risk primarily arise certain intercompany sale purchase transaction expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million million december december respectively reduce earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive loss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information refer item financial statement supplementary datanote financial instrument fair value measurement interest rate risk use fixedtofloate interest rate swap contract designate fair value hedge provide appropriate balance fix float rate debt use cross currency interest rate swap contract designate hedge company net investment japan subsidiary fair value contract marketable debt security analyze yearend determine sensitivity interest rate change sensitivity analysis basis point increase shortterm longterm interest rate december december expect adverse impact earning material estimate increase basis point longterm interest rate december december decrease fair value longterm debt billion million respectively credit risk monitor investment counterpartie objective minimize concentration credit risk investment policy invest institution meet high credit quality standard establish limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information refer item financial statement supplementary datanote financial instrument fair value measurement item financial statement supplementary datum bristolmyer squibb company consolidate statement earning dollar million share datum year end december earning net product sale alliance revenue total revenue cost product solda marketing sell administrative research development amortization acquire intangible asset incomeexpense net total expense earning income taxis provision income taxis net earning noncontrolle interest net earning attributable bms earning common share basic dilute exclude amortization acquire intangible asset consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation total comprehensive incomeloss comprehensive income comprehensive incomeloss attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable debt security receivables inventory current asset total current asset property plant equipment goodwill intangible asset defer income taxis marketable debt security noncurrent asset total asset liability current liability shortterm debt obligation account payable current liability total current liability defer income taxis longterm debt noncurrent liability total liability commitment contingency equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million common share total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization net defer income taxis stockbase compensation impairment charge pension settlement amortization divestiture gain royalty asset acquisition charge equity investment gainslosse contingent consideration fair value adjustment adjustment change operate asset liability receivable inventory account payable deferred income income taxis payable net cash provide operating activity cash flow invest activity sale maturity marketable debt security purchase marketable debt security capital expenditure divestiture proceed acquisition payment net cash acquire net cash investing activity cash flow financing activity shortterm debt obligation net issuance longterm debt repayment longterm debt repurchase common stock dividend net cash provide byused financing activity effect exchange rate cash cash equivalent restrict cash increase cash cash equivalent restrict cash cash cash equivalent restrict cash beginning year cash cash equivalent restrict cash end year accompany note integral consolidated financial statement note accounting policy recently issue accounting standard basis consolidation consolidate financial statement prepare conformity gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date refer summary abbreviate term end term document alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible discovery development manufacturing supply product regional commercial organization market distribute sell product business support global corporate staff function consistent bms operational structure chief executive officer ceo chief operating decision maker manage allocate resource global corporate level manage allocate resource global corporate level enable ceo assess overall level resource available well deploy resource function therapeutic area regional commercial organization research development project line overarch longterm corporatewide strategic goal product franchise basis determination single segment consistent financial information regularly review ceo purpose evaluate performance allocate resource set incentive compensation target planning forecast future period information product regional revenue note revenue use estimate judgment preparation financial statement require use management estimate judgment assumption significant assumption estimate determine accounting business combination impairment goodwill intangible asset sale rebate return accrual legal contingency income taxis actual result differ estimate reclassification certain prior period amount reclassify conform current period presentation include separate presentation amortization acquire intangible asset reclassification asset liability change report total asset liability reclassification impact net asset net earning operating cash flow cash cash equivalent restrict cash cash cash equivalent include bank deposit time deposit commercial paper money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value cash restrict withdrawal general use contractually legally restrict determination current noncurrent classification base expect duration restriction restrict cash consist escrow litigation settlement fund restrict annual company contribution define contribution plan restrict cash million include cash cash equivalent restrict cash december consolidate statement cash flow marketable debt security marketable debt security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity marketable debt security review impairment assess decline market value investment carry value temporary consider intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value cost investee financial condition investment equity security investments equity security readily determinable fair value record fair value change fair value record incomeexpense net investment equity security readily determinable fair value record cost minus impairment plus minus change estimate fair value result observable price change orderly transaction identical similar investment issuer change estimate fair value investment equity security readily determinable fair value record incomeexpense net investment own company account equity method accounting ability exercise significant influence operate financial decision investee maintain share net income loss equity investment account equity method include incomeexpense net investment equity security readily determinable fair value investment equity account equity method assess potential impairment quarterly basis base qualitative factor inventory valuation inventory state low average cost net realizable value property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique unobservable fair value input discount value estimate future cash flow capitalize software eligible cost obtain internal use software capitalize amortize estimate useful life software acquisition business acquire consolidate obtain control fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill business acquisition cost expense incur contingent consideration potential development regulatory approval salesbase milestone salesbase royalty include purchase price business combination exclude asset acquisition amount allocate lead investigational compound asset acquisition expense date acquisition goodwill acquire inprocess research development intangible asset fair value acquire intangible asset determine incomebased approach refer excess earning method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize goodwill tested annually impairment assess qualitative factor determine likely fair value net asset carry amount example qualitative factor assess include bms share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value impairment charge recognize extent carry value iprd determine exceed fair value restructure restructuring charge recognize result action streamline operation reduce number facility estimate impact restructuring plan include future termination benefit integration expense exit cost require judgment actual result vary estimate restructure charge recognize meet certain criterion include finalization commit plan reliable estimate discussion local work council certain market contingency loss contingency legal proceeding claim occur government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incur revenue recognition refer note revenue detailed discussion accounting policy relate revenue recognition include defer revenue royalty refer note alliance detail alliance research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur research development cost present net reimbursement alliance partner upfront contingent development milestone payment asset acquisition investigational compound include research development expense alternative future use advertising product promotion cost advertising product promotion cost expense incurred advertising product promotion cost include marketing sell administrative expense million million million foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize comprehensive incomeloss income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement cash flow payment license asset acquisition investigational compound include operating activity outlicense proceed payment acquisition ownership interest legal entity include acquisition meet accounting definition business include investing activity divestiture proceed royalty consideration receive subsequent relate sale asset business adjustment reflect operating activity include divestiture gain loss relate royalty asset acquisition charge gain loss equity investment gain loss debt redemption recently adopt accounting standard lease amend guidance lease accounting adopt january modify retrospective method cumulative effect change recognize retain earning period adoption new guidance require entity recognize rightofuse asset lease liability initially measure present value future lease payment cumulative effect accounting change material bms elect package practical expedient adoption apply practical expedient separate lease nonlease component new modify lease commence adoption addition bms apply shortterm lease recognition exemption lease term inception great month amend guidance result recognition operating lease rightofuse asset lease liability impact bmss result operation refer note lease information goodwill impairment testing amend guidance simplifie recognition measurement goodwill impairment loss eliminate step quantitative goodwill impairment test adopt prospectively quarter amend guidance goodwill impairment loss recognize report unit carry include goodwill exceed fair value allocate goodwill adoption amend guidance impact bmss result operation recently issue accounting standard adopt financial instrument measurement credit loss june fasb issue amend guidance measurement credit loss financial instrument entity require use forwardlooke estimate loss model availableforsale debt security credit loss recognize allowance reduction amortize cost guidance effective january modify retrospective approach amend guidance material impact bmss result operation note revenue follow table summarize disaggregation revenue nature year end december dollar million net product sale alliance revenues revenues total revenue net product sale represent bmss total revenue year end december product sell principally wholesaler distributor less extent directly retailer hospital clinic government agency pharmacie customer order generally fulfil day receipt result minimal order backlog contractual performance obligation usually limit transfer control product customer transfer occur shipment receipt product consider customer obtain legal title product bms obtain right payment point customer able direct use obtain substantially remain benefit product gross revenue large pharmaceutical wholesaler percentage global gross revenue follow year end december mckesson corporation amerisourcebergen corporation cardinal health inc wholesaler initially invoice contractual list price payment term typically day base customary practice country revenue reduce wholesaler list price time recognition expect chargeback discount rebate sale allowance product return refer gtn adjustment reduction attribute commercial arrangement manage healthcare organization government program medicare medicaid b drug pricing program contain pricing implication mandatory discount pricing protection wholesaler list price discount medicare beneficiarie coverage gap addition nonus government program include different pricing scheme cost cap volume discount outcomebase pricing pricing clawback determine sale individual company aggregation company participate specific market chargeback cash discount reflect reduction receivables settle issuance credit customer typically month rebate discount adjustment include medicaid medicare reflect liability settle cash payment customer typically time period range month year significant judgment require estimate gtn adjustment consider legal interpretation applicable law regulation historical experience payer channel mix current contract price applicable program unbilled claim processing time lag inventory level distribution channel follow table summarize gtn adjustment year end december dollar millions gross product sale gtn adjustmentsa chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale include adjustment provision product sale prior period result change estimate million million million year end december respectively alliance revenue consist primarily amount relate collaboration outlicense arrangement arrangement evaluate represent contract scope revenue recognition guidance entirety contain aspect scope guidance directly reference base application guidance relate derecognition nonfinancial asset asc performance obligation identify separate party benefit directly right good service readily available resource right good service highly interdependent interrelate transaction price arrangement include fix upfront amount variable consideration contingent development regulatory milestone salesbase milestone royalty likely method estimate contingent development regulatory salesbase milestone ultimate outcome binary nature expect value method estimate royalty broad range potential outcome exist instance royalty relate license variable consideration include transaction price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve significant judgment require estimating variable consideration recognize assess factor outside bmss influence likelihood regulatory success limited availability party information expect duration time resolution lack relevant past experience historical practice offering fee concession large number broad range possible amount extent arrangement include multiple performance obligation separable transaction price assign distinct performance obligation reflective relative standalone selling price recognize point time transfer control type outlicense arrangement typically utilize arrangement bms outlicense intellectual property party performance obligation arrangement include license additional performance obligation supply product request party collaboration arrangement include transfer license party jointly develop commercialize product outlicense arrangement consist single performance obligation satisfy execution agreement development commercialization right transfer party upfront fee recognize immediately include incomeexpense net contingent development regulatory milestone amount assess period likelihood achievement typically constrain recognize uncertainty subsequently resolve milestone include incomeexpense net salesbase milestone royalty recognize milestone achieve subsequent sale occur salesbased milestone include incomeexpense net royalty include alliance revenue certain outlicensing arrangement include contingent performance obligation supply commercial product party request license supply obligation account separate performance obligation consider distinct party benefit license supply resource readily available obligation separately identifiable obligation contract accordance revenue recognition guidance consider standalone selling price situation upfront fee contingent development regulatory milestone amount salesbase milestone royalty allocate license recognize manner describe consideration supply obligation usually base stipulate costplus margin contractual term represent standalone selling price supply consideration recognize point time transfer control product party include alliance revenue fee allocation license supply represent consideration bms expect entitle satisfaction separate performance obligation collaboration arrangement unique nature party active participant operating activity expose significant risk reward depend commercial success activity performance obligation inherent arrangement include transfer certain development commercialization right ongoing development commercialization service product supply obligation certain product supply obligation consider distinct account separate performance obligation similar manner discuss performance obligation consider distinct combine single performance obligation transfer right highly integrate interrelate bms obligation jointly develop commercialize product party result upfront fee recognize ratably time expect period collaboration activity include incomeexpense net license combine development commercialization obligation contingent development regulatory milestone long constrain recognize similar manner prospective basis royalty profit sharing recognize underlie sale profit occur include alliance revenue refer note alliance information follow table summarize disaggregation revenue product region year end december dollar millions prioritize brand revlimid eliquis opdivo orencia pomalystimnovid sprycel yervoy abraxane empliciti inrebic establish brand baraclude vidaza brandsa total revenues united states europe rest world otherb total revenue include bms celgene product b revenue include royalty alliancerelate revenue product sell bms regional commercial organization contract asset primarily estimate future royalty termination fee eligible licensing exclusion recognize adoption asc asc contract asset reduce receivable increase period underlie sale occur cumulative catchup adjustment revenue affect contract asset contract liability material year end december revenue recognize performance obligation satisfy prior period million million year end december respectively consist primarily royalty outlicense arrangement revise estimate gtn adjustment relate prior period sale contract asset material december sale commission incremental cost obtain customer contract expense incur amortization period year note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage right obligation party global limited geographic region bms refer collaboration alliance partner alliance partner common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bms contractual share thirdparty sale andor royalty income include alliance revenues sale commercial product consider bms ongoing major central operation refer note revenue information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenues sale commercial product consider bms ongoing major central operation profit share royalty salesbase fee payable bms alliance partner include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development approval milestone payable bms alliance partner investigational compound commercial product defer amortize expect period bms development copromotion obligation market exclusivity period period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present incomeexpense net activity perform time relate sale commercial product include bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation upfront contingent approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense royalty contingent consideration payable bms alliance partner relate divestiture business include incomeexpense net earn payment bms alliance partner present cash flow operating activity select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative research development incomeexpense net select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include unamortized upfront milestone payment specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election statement earning classification amount attributable payment party pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discover bms pfizer fund development cost depend study profit loss share equally global basis certain country pfizer commercialize eliquis pay bms sale base fee coexclusive license right grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms pfizer manufacture product alliance bms principal end customer product sale significant country europe canada australia china japan south korea bms transfer commercialization right pfizer certain small country order simplify operation transfer country bms supply product pfizer cost plus percentage net sale price endcustomer record transfer control product pfizer bms allocate consideration right transfer pfizer right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement global alliance treat single unit accounting upfront proceed subsequent contingent milestone proceed amortize expect period bms copromotion obligation market exclusivity period bms receive million nonrefundable upfront milestone licensing payment relate eliquis december amortization eliquis defer income include incomeexpense net eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing incomeexpense net amortization defer income select alliance balance sheet information december dollar million receivables account payable deferred income otsuka bms otsuka copromote sprycel eu bms responsible development manufacture product principal end customer product sale fee pay otsuka base net sale level oncology territory japan eu equate million billion annual net sale plus net sale excess billion summarize financial information relate alliance follow year end december dollar million revenue otsuka alliance net product sale oncology territory payment otsuka cost product sell oncology fee ono bms ono jointly develop commercialize opdivo yervoy bms investigational compound japan south korea taiwan bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay sale partys assign customer ono grant bms exclusive license development commercialization ono onos prostaglandin e receptor antagonist bms acquire worldwide right japan south korea taiwan add exist collaboration china asean country ono retain exclusive right bms pay million ono include research development expense ono eligible receive subsequent clinical regulatory salesbase milestone payment million royalty country bms exclusive licensing right bms provide ono right accept nktr alliance completion phase clinical study opdivo nktr ono territory right exercise ono partially reimburse bms development cost incur study share certain future development cost contingent milestone payment profit loss collaboration nektar ono exercise right accept nktr alliance bms summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenue bms principal end customer product sale exclusive right develop manufacture commercialize opdivo worldwide japan south korea taiwan ono entitle receive royalty north america territory exclude country list subject customary adjustment nektar bms nektar commence worldwide license collaboration development commercialization bempegaldesleukin nktr nektar investigational immunostimulatory therapy design selectively expand specific cancerfighting cell natural killer cell directly tumor micro environment january party amend collaboration agreement opdivo nktr combination therapy currently phase iii clinical study melanoma muscleinvasive bladder cancer rcc joint development plan agree party original agreement update january amendment specify development certain indication tumor type party responsible supply product bms share development cost associate therapy comprise bms medicine combination nktr subject certain cost cap nektar january amendment retain cost sharing percentage original agreement party jointly commercialize therapy subject regulatory approval bms share global nktr profit loss subject certain annual loss cap nektar bm pay nektar billion right discuss million share nektar common stock represent ownership interest bms equity ownership subject certain lockup standstill voting provision fiveyear period upfront payment allocate equity investment million consider nektar stock price date close current limitation trading security remain billion payment allocate right discuss include research development expense second quarter bms pay billion achievement contingent development regulatory salesbase milestone life alliance period research development expense payable agreement nektar million million year end december respectively note acquisition divestiture license arrangement acquisition business combination celgene november bms complete celgene acquisition acquisition expect create lead biopharmaceutical company position sustained innovation longterm growth address need patient cancer inflammatory immunologic cardiovascular disease high value innovative medicine lead scientific capability share celgene common stock convert right receive share bms common stock cash celgene shareholder receive tradeable contingent value right cvr share celgene common stock represent right receive cash subject achievement future regulatory milestone aggregate cash pay connection celgene acquisition billion billion net cash acquire bms fund acquisition cash onhand debt proceed describe note financial instrument fair value measurement transaction account business combination require asset acquire liability assume recognize fair value acquisition date purchase price allocation preliminary subject change include valuation inventory property plant equipment intangible asset income taxis legal contingency item amount recognize finalized information necessary complete analysis obtain later year acquisition date total consideration acquisition consist follow amount million share datum total consideration celgene share outstanding november cash share cash consideration outstanding share celgene share outstanding november closing price bms common stock november estimate fair value share consideration celgene share outstanding november close price cvra fair value cvrs fair value replacement option fair value replacement restrict share award fair value cvrs issue option share award holder fair value sharebase compensation award attributable precombination serviceb total consideration transfer closing price cvr base trade november b fair value award attribute postcombination service billion include compensation cost refer note employee stock benefit plan information preliminary purchase price allocation result follow amount allocate asset acquire liability assume acquisition date base respective preliminary fair value summarize preliminary purchase price dollar million allocation cash cash equivalent receivables inventory property plant equipment intangible assetsa otezla asset heldforsaleb asset account payable income taxis payable deferred income tax liability debt liability identifiable net asset acquire goodwillc total consideration transfer intangible asset consist currently market product right approximately billion amortize year calculate weightedaverage useful life asset iprd approximately billion amortize value multiperiod excess earning method method starts forecast expect future net cash flow associate asset involve adjust forecast present value apply appropriate discount rate reflect risk factor associate cash flow stream b include million inventory billion develop product right million accrue liability million noncurrent liability refer divestiture information c goodwill represent goingconcern value associate future product discovery exist pipeline expect value synergy result cost saving avoidance attribute identifiable asset goodwill deductible tax purpose bms consolidated statement earning year end december include billion revenue billion net loss associate result operation celgene acquisition date december acquisition expense million year end december include financial advisory legal proxy filing regulatory financing fee hedge cost follow unaudited pro forma information prepare celgene acquisition otezla divestiture occur january unaudited supplemental pro forma consolidated result purport reflect combine company result operation project future result operation combine company unaudite supplemental pro forma consolidated result reflect historical financial information bms celgene adjust effect celgene acquisition otezla divestiture occur january primarily follow adjustment amortization expense primarily relate fair value adjustment celgene intangible asset inventory debt nonrecurre acquisitionrelate cost directly attributable celgene acquisition tax expense directly attributable otezla divestiture interest expense include amortization defer financing fee attributable celgene acquisition financing elimination historical revenue expense relate otezla refer divestiture adjustment adjust applicable tax impact estimate weightedaverage statutory tax rate apply applicable pro forma adjustment year end december amount million total revenue net earningsloss asset acquisition certain transaction account asset acquisition determined business term define asc primarily significant process acquire result amount allocate lead investigational compound expense capitalize bms acquire outstanding share ifm therapeutics inc ifm private biotechnology company focus develop therapy modulate novel target innate immune system treat cancer autoimmunity inflammatory disease acquisition provide bms right ifm preclinical sting nlrp agonist program focus enhance innate immune response treat cancer transaction price include upfront payment million contingent consideration billion upfront payment include research development expense million allocate net operating loss tax credit carryforward contingent consideration include development regulatory salesbase milestone payment million include research development expense follow commencement phase clinical study bms pay million additional contingent milestone subsequent product select ifm preclinical sting nlrp agonist programs research development expense include million million result occurrence certain development regulatory event attribute asset acquisition complete prior include flexus biosciences inc cardioxyl pharmaceuticals inc cormorant pharmaceutical divestiture follow table summarize financial impact divestiture include royalty include incomeexpense net revenue pretax earning relate divestiture asset heldforsale material period present exclude divestiture gain loss proceedsa divestiture gain royalty income dollar millions otezla upsa business diabete business erbitux business manufacturing operation plavix avaproavalide investigational hiv business mature brand total include royalty receive subsequent relate sale asset business otezla order complete celgene acquisition bms require ftc div certain product allow acquisition close timely basis light concern express ftc celgene enter purchase agreement amgen august amgen acquire global right otezla apremilast billion cash november bms complete divestiture otezla amgen transaction account asset divestiture otezla acquire celgene acquisition classify heldforsale time acquisition estimate fair value otezla net asset consist billion develop product right million inventory upsa business bm sell upsa consumer health business include share upsa sas bms asset liability relate upsa product portfolio taisho pharmaceutical co ltd transaction account sale business upsa business treat single disposal group heldforsale december diabete business february bms astrazeneca terminate diabetes business alliance agreement bms sell astrazeneca substantially diabete business comprise alliance consideration transaction include tiere royalty payment range base net sale royalty million million million contingent consideration million receive result additional gain achievement regulatory approval milestone september bms transfer percentage future royalty right amylin net product sale cppib transfer right represent approximately potential future royalty bms entitle exchange transfer bms receive additional tieredbase royalty amylin net product sale cppib include million million pay million november bm transfer percentage future royalty right portion onglyza farxiga net product sale royalty pharma transfer right represent approximately potential future royalty bms entitle product exchange transfer bms receive additional tieredbase royalty onglyza farxiga net product sale royalty pharma include million million erbitux business bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux canada japan bms principal end customer product sale north america pay lilly distribution fee erbitux net sale north america plus share certain royalty pay lilly october bms transfer right erbitux north america lilly exchange tiere salesbase royalty september include million million bm transfer cocommercialization right japan merck kgaa exchange salesbase royalty royalty earn million result adoption asc quarter estimate future royalty result transfer right merck kgaa record cumulative effect adjustment retain earning million change estimate future royalty include manufacturing operation bms sell manufacturing packaging facility anagni italy catalent inc transaction account sale business divestiture include transfer facility majority employee site inventory certain thirdparty contract manufacturing obligation asset reduce relative fair value consider purchase price result impairment charge million include cost product sell catalent inc provide certain manufacturing packaging service bms period time bms sell small molecule active pharmaceutical ingredient manufacturing operation sword ireland sk biotek co ltd proceed receive quarter transaction account sale business divestiture include transfer facility majority employee site inventory certain thirdparty contract manufacturing obligation asset reduce relative fair value consider purchase price result impairment charge million include cost product sell sk biotek co ltd provide certain manufacturing service bms period time plavix avaproavalide sanofi reacquire bms codevelopment cocommercialization agreement plavix avaproavalide consideration transfer right include quarterly royalty december million terminal payment receive million allocate optout market million allocate bms interest europe asia territory partnership royalty expect receive portion terminal payment allocate optout market reflect contract asset cumulative effect adjustment adoption asc bm fulfil performance obligation million allocate bms partnership interest defer december recognize transfer sanofi royalty earn sanofi territory cover americas australia optout market present alliance revenue aggregate million million royalty attribute territory cover europe asia earn territory partnership pay bms include equity net lossincome affiliate amount million million investigational hiv business bm sell investigational hiv medicine business consist number rd program different stage discovery development viiv healthcare bm receive million entitle receive viiv healthcare contingent development regulatory milestone payment billion salesbase milestone payment billion future tiere royalty bms earn transitional fee million certain rd service mature brand divestiture include brand sell cheplapharm result proceed million divestiture gain million asset heldforsale follow table summarize upsa consumer health business net asset heldforsale december december dollar million receivable inventory property plant equipment goodwill asset heldforsale account payable current liability defer income taxis liabilitie liability relate asset heldforsale net asset heldforsale licensing arrangement halozyme bms halozyme enter global collaboration license agreement develop subcutaneously administer bms io medicine halozyme enhanze drugdelivery technology technology allow rapid delivery large volume injectable medication subcutaneous delivery bms pay million halozyme access technology include research development expense bms designate multiple io target include pd develop enhanze technology option select additional target year effective date maximum target bms pay contingent development regulatory salesbase milestone million achieve nominate collaboration target additional milestone payment combination product future royalty sale product enhanze technology cytomx bms expand strategic collaboration cytomx discover novel therapy cytomxs proprietary probody platform original collaboration discover develop commercialize probody therapeutic bms select oncology target include ctla pursuant expand agreement cytomx grant bms exclusive worldwide right develop commercialize probody therapeutic additional target bms pay cytomx million right initial target expense rd prior bms pay million cytomx access additional target include research development expense bms reimburse cytomx certain research cost collaboration period pay contingent development regulatory salesbase milestone million achieve collaboration target future royalty biogen bms outlicense biogen exclusive right develop commercialize bms antietau compound development progressive supranuclear palsy alzheimer disease biogen pay million bms include incomeexpense net bms entitle contingent development regulatory salesbase milestone payment million achieve future royalty bms originally acquire right compound acquisition ipierian inc biogen assume bmss applicable remain obligation stockholders ipierian inc roche bms outlicense roche exclusive right develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy roche pay million bms include incomeexpense net roche cease development duchenne muscular dystrophy fstar bms acquire exclusive option purchase fstar lead asset fs antiher antibody fragment development treatment breast gastric cancer welldefine population herpositive patient bms discontinue development fs exercise option result iprd charge million include research development expense attribute noncontrolle interest note incomeexpense net year end december dollar million interest expense pension postretirement royalty licensing income divestiture gain acquisition expense contingent value right investment income integration expense provision restructure equity investment gainslosse litigation settlement transition service fee intangible asset impairment equity net lossincome affiliate loss debt redemption incomeexpense net note restructure restructure integration plan implement initiative realize billion expect cost synergy result cost saving avoidance celgene acquisition synergy expect realize cost product sell marketing sell administrative expense research development expense majority charge expect incur range billion billion cost consist integration planning execution expense employee termination benefit cost accelerate stockbased compensation contract termination cost shutdown cost associate site exit cash outlay connection action expect approximately billion employee workforce reduction approximately follow table summarize charge activity relate celgene acquisition year end dollar million december provision restructure integration expense asset impairment total charge year end dollar million december research development incomeexpense net total charge year end dollar million december liability january provision restructuringa payment liability december exclude million accelerate stockbased compensation october restructuring plan announce evolve streamline bms operating model majority charge expect incur range billion billion consist employee termination benefit cost contract termination cost accelerate depreciation impairment charge cost associate manufacturing rd site exit cash outlay connection action expect approximately total charge charge approximately billion recognize action announcement employee workforce reduction approximately follow table summarize charge activity relate company transformation year end december dollar million employee termination cost termination cost provision restructuring accelerate depreciation asset impairment shutdown cost total charge year end december dollar million cost product sell marketing sell administrative research development incomeexpense net total charge year end december dollar million liability december ceaseuse liability reclassification liability january charge change estimate provision restructure foreign currency translation payment liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provision effective tax rate reconciliation effective tax rate statutory federal income tax rate follow earning income taxis dollar million earning income taxis nonus total statutory rate deem repatriation transition tax defer tax remeasurement global intangible low tax income gilti foreign tax effect certain operation ireland puerto rico switzerland federal valuation allowance federal state foreign contingent tax matter federal research base credit fair value adjustment contingent value right nondeductible rd charge puerto rico excise tax domestic manufacturing deduction state local taxis net valuation allowance foreign total effective tax rate reflect additional tax expense billion recognize enactment act increase effective tax rate effective tax rate include favorable measurement period adjustment provisional amount record associate act million accounting reduction defer tax asset tax rate complete december tax charge deem repatriation transition tax complete december gilti tax associate otezla divestiture million prior enactment act earning certain bmss manufacturing operation low tax jurisdiction switzerland ireland puerto rico indefinitely reinveste result transition tax act bms long indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign state income withholding tax apply bms remain indefinitely reinveste respect financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable bms operate favorable tax grant puerto rico schedule expire prior federal valuation allowance establish result nektar equity investment fair value loss consider limited capital loss federal state foreign contingent tax matter include million tax benefit million tax benefit respect lapse statute fair value adjustment contingent value right deductible tax purpose non deductible rd charge primarily result acquisition relate milestone payment shareholder include flexus biosciences inc cardioxyl pharmaceuticals inc ifm therapeutics inc puerto rico impose excise tax gross company purchase price good sell bmss manufacturer puerto rico excise tax recognize cost product sell intraentity sale occur income tax purpose excise tax deductible result foreign tax credit generally recognize bmss provision income taxis excise tax incur defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward state net operating loss credit carryforward federal net operating loss credit carryforward defer income milestone payment license fee inventory foreign defer tax asset sharebase compensation total defer tax asset valuation allowance defer tax asset net valuation allowance defer tax liability depreciation acquire intangible asset goodwill total defer tax liability defer tax liabilitiesasset net recognize deferred income taxis asset noncurrent defer income taxis liabilitie noncurrent liability relate asset heldforsale total federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance billion establish follow item billion primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal defer tax asset include equity fair value adjustment federal net operating loss carryforward change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition non rate change balance end year income tax payment million million million business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense deem repatriation transition tax liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follows exclude interest penalty year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty accrue interest penalty payable unrecognized tax benefit include current noncurrent income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority propose consider propose material adjustment tax position issue transfer price certain tax credit deductibility certain expense reasonably possible new issue raise tax authority require adjustment unrecognized tax benefit estimate adjustment reasonably time reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit result payment additional taxis adjustment certain defer taxis andor recognition tax benefit follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy japan switzerland uk note earning share year end december amount million share datum net earning attributable bms basic diluted eps calculation weightedaverage common share outstanding basic incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning common share basic diluted note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument quote price identical similar instrument nonactive market additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective nav underlie investment level derivative instrument value libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract level unobservable input little market datum available level financial liability consist acquisition relate contingent consideration success payment relate undeveloped product right result celgene acquisition financial asset liability measure fair value recur basis summarize december december dollar million level level level level level cash cash equivalent money market security marketable debt security certificate deposit commercial paper corporate debt security derivative asset equity investment derivative liability contingent consideration liability contingent value right acquisition relate contingent consideration contingent consideration obligation record estimate fair value bms revalue obligation report period relate contingency resolve contingent value right adjust fair value trade price security end report period fair value measurement contingent consideration liability estimate probabilityweighte discount cash flow approach base significant unobservable input relate product candidate acquire business combination review quarterly input include applicable estimate probability time achieve specify development regulatory milestone estimate annual sale discount rate calculate present value estimate future payment significant change increase decrease probability achieve relate development regulatory event shorten lengthen time require achieve event increase decrease estimate annual sale result correspond increase decrease fair value obligation fair value contingent consideration december calculate follow significant unobservable input range weight average utilize input december discount rate probability payment project year payment development regulatory milestone project year payment salesbased milestone amount calculate percentage annual sale na transfer level year end december follow table represent rollforward fair value level instrument year end dollar million december fair value january celgene acquisition fair value december availableforsale debt security equity investment change fair value equity investment include incomeexpense net follow table summarize bms availableforsale debt security equity investment december december gross unrealized gross unrealized amortize amortize dollar million cost gain loss fair value cost gain loss fair value certificate deposit commercial paper corporate debt security equity investment total december dollar million marketable debt security current current asset marketable debt security noncurrenta noncurrent asset total noncurrent marketable debt security mature year december december equity investment measure fair value exclude table limit partnership equity method investment million december million december equity investment readily determinable fair value million december million december amount include noncurrent asset follow table summarize net gainloss record equity investment readily determinable fair value hold december year end december dollar million net gainloss recognize net gain recognize equity investment sell net unrealized gainloss equity investment hold qualifying hedge nonqualifye derivative cash flow hedge foreign currency forward contract hedge certain forecast intercompany inventory purchase sale transaction certain foreign currency transaction fair value contract designate cash flow hedge temporarily report accumulate comprehensive loss include earning hedge item affect earning adoption amend guidance derivative hedge entire change fair value hedge instrument include assessment hedge effectiveness record derivative qualify cash flow hedge component comprehensive incomeloss net gain loss foreign currency forward contract expect reclassify net earning primarily include cost product sell incomeexpense net month notional outstanding foreign currency forward contract primarily attribute euro billion japanese yen million december earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis foreign currency forward contract designate hedge instrument offset exposure certain foreign currency denominate asset liability earning change fair value derivative recognize earning occur bms hedge portion future foreign currency exposure utilize strategy involve purchase local currency option write local currency option account hedge future sale denominate local currency specifically bms sell write local currency option purchase local currency option expiration date local currency notional amount different strike price premium collect sale option equal premium pay purchase option result net premium pay combination transaction generally refer zerocost collar expiration date notional amount correspond timing forecast foreign currency sale foreign currency zerocost collar contract outstanding december settlement date month dollar weaken relative currency hedge anticipate sale purchase option value reduce zero benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write form upper end collar net investment hedge nonus dollar borrowing million billion december designate net investment hedge hedge euro currency exposure net investment certain foreign affiliate recognize longterm debt effective portion foreign exchange gain remeasurement euro debt include foreign currency translation component accumulate comprehensive loss relate offset long term debt january million crosscurrency interest rate swap contract mature december enter designate hedge japanese yen currency exposure bms net investment japan subsidiary contract fair value change record foreign currency translation component comprehensive incomeloss relate offset noncurrent asset noncurrent liability fair value hedge fix float interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread gain loss result change fair value underlie debt attributable hedge benchmark interest rate risk record interest expense associate offset carry value debt specific term notional swap intend align debt hedge change fair value swap record interest expense associate offset derivative asset liability consolidate balance sheet result net impact earning underlie swap terminate prior maturity fair value adjustment underlie debt amortize reduction interest expense remain term debt follow announcement celgene acquisition forward start interest rate swap option contract enter total notional value billion hedge future interest rate risk associate anticipate issuance longterm debt fund acquisition april deal contingent forward start interest rate swap contract enter aggregate notional principal billion hedge interest rate risk associate anticipate issuance longterm debt fund acquisition forward start interest rate swap option contract terminate deal contingent forward start interest rate swap contract terminate completion celgene acquisition follow summarize fair value outstanding derivative december december asseta liabilityb asseta liabilityb dollar million notional fair value notional fair value notional fair value notional fair value derivative designate hedge instrument interest rate swap contract crosscurrency interest rate swap contract foreign currency forward contract derivative designate hedge instrument foreign currency forward contract foreign currency zerocost collar contract include current asset noncurrent asset b include current liability noncurrent liability follow table summarize financial statement classification gainloss recognize hedging instrument year end december cost incomeexpense cost incomeexpense cost incomeexpense dollar million product sell net product sell net product sell net interest rate swap contract crosscurrency interest rate swap contract foreign currency forward contract forward start interest rate swap option contract deal contingent forward start interest rate swap contract foreign currency zerocost collar contract follow table summarize effect derivative nonderivative instrument designate hedge instrument comprehensive incomeloss year end december dollar million derivative qualify cash flow hedge foreign currency forward contract gainloss recognize comprehensive incomelossa reclassify cost product sell reclassify incomeexpense net derivative qualify net investment hedge crosscurrency interest rate swap contract gainloss recognize comprehensive incomeloss nonderivative qualify net investment hedge non dollar borrowing gainloss recognize comprehensive incomeloss expect reclassify earning month debt obligation bm issue aggregate principal approximately billion float rate fix rate unsecured senior note proceed net discount defer loan issuance cost billion note rank equally right payment bms exist future senior unsecured indebtedness fix rate note redeemable time vary specify redemption price plus accrue unpaid interest bms issue aggregate principal billion senior unsecured note register public offering proceed net discount defer loan issuance cost billion note rank equally right payment bms exist future senior unsecured indebtedness redeemable time vary specify redemption price plus accrue unpaid interest connection celgene acquisition bm commence offer exchange outstanding note issue celgene approximately billion likeamount new note issue bms exchange offer exchange transaction account modification assume debt instrument follow settlement exchange offer bms issue approximately billion new note exchange celgene note tender exchange offer aggregate principal celgene note remain outstanding follow settlement exchange offer approximately billion fair value longterm debt billion billion december respectively value level input base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument repayment note maturity aggregate billion million interest payment million million million december bm separate revolve credit facility total billion consist day billion facility renew january billion facility expire january fiveyear billion facility extend september july respectively facility provide customary term condition financial covenant provide backup liquidity bms commercial paper borrowing bms billion facility billion revolving facility extendable annually year anniversary date consent lender bms day billion facility renew year anniversary date subject certain term condition borrowing outstanding revolve credit facility december bms enter billion term loan credit agreement consist billion day tranche billion threeyear tranche billion year tranche connection celgene acquisition term loan subject customary term condition financial covenant proceed term loan fund portion cash pay celgene acquisition payment relate fee expense subsequent completion acquisition bms repay term loan entirety cash proceed generate otezla divestiture refer note acquisition divestiture license arrangement information available financial guarantee provide form bank overdraft facility standby letter credit performance bond approximately million december standby letter credit issue financial institution support guarantee obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action shortterm debt obligation include december dollar millions nonus shortterm borrowing current portion longterm debt total longterm debt current portion longterm debt include december dollar million principal value note note float rate note note note note note note float rate note note note note note note note note note note note note euro note note note note note note note note euro note note note note note note note note note note note note note note mature total december dollar million principal value adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount issuance cost unamortized purchase price adjustment celgene debt total current portion longterm debt longterm debt total note receivables december dollar million trade receivable chargeback cash discount bad debt allowance net trade receivables alliance royalty vat receivables nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent approximately total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year celgene acquisition provision utilization balance end year note inventory december dollar million finished good work process raw packaging material total inventory inventory noncurrent asset prior year amount certain inventory balance present work process conform current year presentation finish good raw material total inventory include fair value adjustment result celgene acquisition billion recognize future period non current asset include inventory expect remain hand year period note property plant equipment december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment united states europe rest world total depreciation expense million million million note lease lease facility office research development storage distribution purpose comprise approximately total lease obligation lease term vary base nature operation market dynamic country lease facility classify operating lease remain lease term year year lease contain specific renewal option period range year year notice renew provide advance lease expiration automatic renewal advance notice require period cover option extend lease include noncancellable lease term exercise option determine reasonably certain certain lease contain termination option provide flexibility terminate lease ahead expiration sufficient advance notice period cover option terminate lease include non cancellable lease term exercise option determine reasonably certain judgment require assess renewal termination option reasonably certain exercise factor consider contractual term compare current market rate leasehold improvement expect significant value cost terminate lease importance facility operation cost determine variable base index rate include measurement real estate lease liability variable cost include real estate taxis insurance utility common area maintenance operating cost implicit rate lease readily determinable incremental borrowing rate apply portfolio approach discount real estate lease liability remain lease obligation comprise vehicle primarily salesforce rd facility operate party management direction vehicle lease term vary country term generally year year follow table summarize component lease expense year end dollar million december operating lease cost variable lease cost shortterm lease cost sublease income total operating lease expense operating lease rightofuse asset liability follow december january dollar millions noncurrent asset current liability noncurrent liability total liability future lease payment noncancellable operating lease december follow dollar million total future lease payment imputed interest total lease liability future minimum lease payment noncancelable operating lease december approximately million year million rightofuse asset obtain exchange new operating lease obligation million year end december primarily relate million rightofuse asset acquire celgene acquisition cash pay amount include measurement operating lease liability million year end december net million lease incentive receive second quarter weightedaverage remain lease term year discount rate december note goodwill intangible asset december estimate dollar million useful life goodwilla intangible assetsa license year acquire develop product right year capitalize software year iprd gross intangible asset accumulate amortization intangible asset include goodwill intangible asset recognize celgene acquisition refer note acquisition divestiture license arrangement information relate celgene acquisition amortization expense intangible asset million million million future annual amortization expense intangible asset expect approximately billion billion billion billion billion intangible asset impairment charge million million million million iprd impairment charge record research development follow decision discontinue development investigational compound obtain acquisition medarex million impairment charge record incomeexpense net outlicensed asset obtain acquisition zymogenetics inc meet primary endpoint phase ii clinical study million iprd impairment charge recognize attribute noncontrolle interest option purchase fstar exercise note supplemental financial information december dollar millions prepaid refundable income taxis research development asset heldforsale current asset december dollar million equity investment inventory operate lease pension postretirement restrict cash noncurrent asset december dollar million rebate return income taxis payable employee compensation benefit research development dividend interest royalty operating lease current liability december dollar million income taxis payable contingent value right pension postretirement operating lease defer income defer compensation noncurrent liability note equity common stock accumulate treasury stock capital excess par value comprehensive retain noncontrolle dollar share million share par value stock loss earning share cost interest balance january accounting change cumulative effecta adjust balance january net earnings comprehensive incomeloss cash dividend declaredc share repurchase program stock compensation variable interest entity distribution balance december accounting change cumulative effectb adjusted balance january net earnings comprehensive incomeloss cash dividend declaredc share repurchase program stock compensation adoption asu b distribution balance december accounting change cumulative effectb adjusted balance january net earnings comprehensive incomeloss celgene acquisition cash dividend declaredc share repurchase program stock compensation distribution balance december cumulative effect result adoption asu b cumulative effect result adoption asu c cash dividend declare common share respectively bms share repurchase program authorize board director allow repurchase share effect open market privately negotiate transaction compliance rule b securities exchange act amended exchange act include rule b trading plan share repurchase program expiration date suspend discontinue time treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method fourth quarter bm execute accelerated share repurchase agreement asr morgan stanley co llc barclays bank plc repurchase aggregate billion common stock asr fund cash onhand approximately million share common stock represent approximately billion aggregate repurchase price current stock price deliver bms include treasury stock agreement expect settle second quarter additional share common stock deliver bms certain circumstance bms require cash payment elect deliver share common stock counterpartie total number share ultimately repurchase asr determine final settlement base discount volumeweighte average price bmss common stock asr period bms complete accelerated share repurchase agreement repurchase approximately million share common stock aggregate billion agreement fund combination debt cash component comprehensive incomeloss follow year end december dollar million pretax tax tax pretax tax tax pretax tax tax derivative qualify cash flow hedge unrealize gainslosse reclassify net earningsa derivative qualify cash flow hedge pension postretirement benefit actuarial lossesgain amortizationb settlementsb pension postretirement benefit availableforsale security unrealize gainslosse realize lossesgainsb availableforsale security foreign currency translation comprehensive incomeloss include cost product sell b include incomeexpense net accumulate balance relate component comprehensive incomeloss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation accumulate comprehensive loss note retirement benefit bms sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan plan cover employee future benefit relate service plan eliminate bms contribute minimum require erisa plan benefit base primarily participant year credit service final average compensation december bms announce plan fully terminate plan pension obligation relate plan distribute combination lump sum payment eligible plan participant elect payment purchase group annuity contract wholly own insurance subsidiary athene holding ltd athene billion distribute plan participant elect lump sum payment election window group annuity contract purchase athene billion remain plan participant athene irrevocably assume pension obligation transaction fully terminate plan result billion noncash pretax pension settlement charge bms acquire celgene november certain celgene international subsidiary fund unfunded define benefit pension plan record fair value celgene plan assumption accounting policy consistent disclose bms acquisition excess project benefit obligation plan asset recognize liability previously exist defer actuarial gain loss unrecognize service cost benefit eliminate net periodic benefit costcredit define benefit pension plan include year end december dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial loss settlement curtailment special termination benefit net periodic pension benefit costcredit pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan change define benefit pension plan obligation asset fund status amount recognize consolidated balance sheet follow year end december dollar million benefit obligation begin year service costbenefit earn year interest cost settlement curtailment actuarial lossesgain benefit pay acquisitiondivestiture foreign currency benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution settlement benefit pay asset transfer acquisitiondivestiture foreign currency fair value plan asset end year unfundedfunded status assetsliabilitie recognize noncurrent asset current liability noncurrent liability fund status recognize accumulate comprehensive loss net actuarial loss prior service credit total accumulate benefit obligation define benefit pension plan billion billion december respectively additional information relate pension plan follow december dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine define benefit pension plan obligation follow december discount rate rate compensation increase weightedaverage actuarial assumption determine define benefit pension plan net periodic benefit costcredit follow year end december discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citi pension discount curve develop discount rate plan expect return plan asset assumption plan base management expectation longterm average rate return achieve underlying investment portfolio factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset actuarial loss relate plan benefit obligation primarily result decrease discount rate actuarial gain relate plan benefit obligation primarily result increase discount rate gain loss amortize life expectancy plan participant plan year expect remain service period plan extent exceed high marketrelated value project benefit obligation respective plan postretirement benefit plan comprehensive medical group life benefit provide substantially legacy bms retiree elect participate comprehensive medical group life plan less extent certain benefit nonus employee medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally fixedincome security postretirement benefit plan obligation million million december respectively fair value plan asset million million december respectively weightedaverage discount rate determine benefit obligation december respectively net periodic benefit credit material plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total plan asset equity security equity fund fix income fund corporate debt security treasury agency security shortterm investment fund insurance contract cash cash equivalent plan asset subject leveling plan asset measure nav practical expedient venture capital limited partnership total plan asset measure nav practical expedient net plan asset investment valuation policy investment class follow level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input utilize observable price similar instrument quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund shortterm investment fund classify level fair value hierarchy value nav share hold year end represent fair value corporate debt security treasury agency security classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available insurance contract hold certain foreign pension plan carry contract value approximate estimate fair value base fair value underlie investment insurance company essentially venture capital limited partnership investment liquidate end remain investment practical expedient consist multiasset fund redeemable daily weekly monthly basis investment strategy maximize return maintain appropriate level risk provide sufficient liquidity benefit obligation plan expense individual plan investment allocation determine local fiduciary committee composition total asset pension plan december broadly characterize allocation equity security debt security investment principal define benefit pension plan overfunde termination result excess plan asset million reflect bms asset december asset primarily report long term restrict cash election contribute asset bristolmyers squibb saving investment program qualified replacement plan election require asset fund future annual company contribution bristol myers squibb saving investment program contribution estimate future benefit payment contribution pension plan million million million expect material estimate annual future benefit payment nonterminate plan include lump sum payment approximately million year subsequent year period saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense attribute define contribution plan approximately million note employee stock benefit plan shareholder approve plan replace stock incentive plan plan provide million share authorize grant plus share outstanding award plan february expire forfeit cancel withhold satisfy tax withholding obligation december million share available award share issue treasury stock satisfy bms obligation plan celgene acquisition bms assume stock incentive plan equity incentive plan refer bms plan plan plan provide grant option restrict stock unit rsus performance share unit psus sharebase performancebase award celgene employee officer nonemployee director additionally term plan provide accelerate vest award change control follow involuntary termination cause acquisition date million share available award celgene plan outstanding celgene equity award assume bms convert bms equity award replacement bms award generally term condition include vest celgene award exchange share issue treasury stock satisfy bms obligation plan cvr issue holder vest unexercised money option outstanding acquisition date celgene rsu holder unveste money option outstanding acquisition date award vest prior march eligible receive cvrs celgene rsu holder unveste money option outstanding acquisition date award vest march eligible receive cash value preconverte celgene rsu money option cvr milestone achieve executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price primarily utilize treasury share satisfy exercise stock option rsus grant key employee subject restriction continuous employment generally vest occur ratably year period grant date stock unit right receive stock end specify vest period voting right market share unit msus grant executive vest condition continuous employment vest date payout factor share price award date payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year psus grant executive year cycle grant target number unit subject adjustment number share issue psus vest determine base achievement performance goal base bms threeyear total shareholder return relative peer group company vest condition continuous employment occur anniversary grant date stockbase compensation expense award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate component stockbase compensation benefit consolidate statement earning follow year end december dollar million cost product sell marketing sell administrative research development incomeexpense net total stockbase compensation expense income tax benefit total stockbase compensation expense year end december include million relate celgene postcombination service period million accelerate vest award relate celgene acquisition include million relate cvr obligation unvested stock award post combination service period refer note acquisition divestiture license arrangement information relate celgene acquisition replacement stock option grant celgene option holder acquisition issue consistent vest condition replace award replacement stock option contractual term year initial grant date majority stock option outstanding vest onefourth increment year period certain award cliff vest long short service period celgene option holder elect exercise option time option term share purchase vested date exercise shall subject forfeiture lapse accordance establish vest time period fair value acquisition date attributable postcombination service adjust estimate forfeiture recognize expense straightline basis remain vest period bms estimate fair value replacement option black schole option pricing model follow assumption year end december weight average riskfree interest rate expect volatility weight average expect term year expect dividend yield riskfree interest rate base rate available federal reserve treasury constant maturity remain term equal option expect life time replacement award expect volatility replacement stock option award estimate base blend imply volatility year historical volatility bms publicly trade stock expect term employee share option period time option expect outstanding base historical forecast exercise behavior dividend yield estimate base bms annual dividend rate time award replacement follow table summarize stock compensation activity year end december stock optionsa restrict stock unit market share unit performance share unit weight weight weight weight average number average number average number average number exercise price nonveste grantdate nonveste grantdate nonveste grantdate share million option share award fair value award fair value award fair value balance january replacement award grant releasedexercised adjustment actual payout forfeitedcancele balance december expect vest december substantially million unvested stock option weightedaverage exercise price expect vest restrict performance share dollar million stock option stock unit market share unit unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share stock option replacement award restrict stock unit replacement award restrict stock unit market share unit performance share unit fair value award vest restricted stock unit replacement award restrict stock unit market share unit performance share unit total intrinsic value stock option exercise fair value rsus msus psus approximate close trading price bms common stock grant date adjust unit eligible accrue dividend addition fair value msus psus consider probability satisfy payout factor total shareholder return respectively fair value replacement rsus approximate close trading price bms common stock date acquisition adjust unit eligible accrue dividend fair value acquisition date attributable postcombination service adjust estimate forfeiture recognize expense straightline basis remain vest period follow table summarize significant outstanding exercisable option december weightedaverage number option remain contractual weightedaverage exercise aggregate intrinsic value range exercise price million life year price share million outstanding exercisable aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december note legal proceeding contingency bms certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business claim proceeding involve type party include government competitor customer supplier service provider licensee employee shareholder matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial contractual right licensing obligation health safety matter consumer fraud employment matter product liability insurance coverage resolution matter develop long period time expectation change result new finding ruling appeal settlement arrangement legal proceeding significant bms believe significant material describe bms believe matter specifically note material adverse effect financial position liquidity bms believe substantial defense matter outcomes bmss legal proceeding contingency inherently unpredictable subject significant uncertainty assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material bmss financial position result operation cash flow particular period furthermore failure enforce bmss patent right likely result substantial decrease respective product revenue generic competition note bms unable assess outcome respective matter able estimate possible loss range loss potentially result matter contingency accrual recognize probable liability incur relate loss reasonably estimate development legal proceeding matter cause change amount previously accrue evaluated reporting period discussion bmss tax contingency note income taxis intellectual property abraxane november celgene receive notice letter hbt labs inc hbt notify celgene file b nda contain paragraph iv certification certain patent list fda orange book abraxane hbt seek market generic version abraxane response celgene initiate patent infringement action drug price competition patent term restoration act know hatchwaxman act hbt district court district delaware hbt file answer counterclaim assert patent invalid andor infringe february celgene enter settlement hbt terminate patent litigation settlement celgene agree provide hbt license patent require manufacture sell generic paclitaxel proteinbound particle injectable suspension product begin september june celgene receive notice letter sun pharma advanced research company ltd sparc notify celgene file b nda contain paragraph iv certification certain patent list fda orange book abraxane sparc seek market paclitaxel injection concentrate suspension product response celgene initiate patent infringement action hatchwaxman act sparc district court district new jersey august december celgene voluntarily dismiss action prejudice antipd antibody litigation september danafarber cancer institute danafarber file complaint district court district massachusetts seek correct inventorship relate patent direct method treat cancer pd pdl antibodie specifically danafarber seeking add scientist inventor patent october pfizer allow intervene case allege scientist identify danafarber employ company eventually acquire pfizer relevant period february bms settle lawsuit pfizer bench trial lawsuit danafarber take place february court issue opinion rule scientist add inventor patent decision appeal federal circuit june dana farber file new lawsuit district massachusetts bms seek damage result court decision add scientist inventor case stay pende outcome bmss appeal federal circuit car litigation october day fda approve kite pharma incs kite yescarta product juno sloan kettering institute cancer research ski file complaint kite district court central district california complaint allege yescarta infringe certain claim patent patent concern car cell technology kite file answer counterclaim assert noninfringement invalidity patent december follow eightday trial jury reject kite defense find kite willfully infringe patent award juno ski reasonable royalty consist million upfront payment run royalty kite sale yescarta expiration patent august briefing posttrial motion schedule complete february eliquis bms receive notice letter twentyfive generic company notify bms file anda contain paragraph iv certification seek approval generic version eliquis result eliquis patent list fda orange book challenge composition matter patent claim apixaban specifically formulation patent response bms partner pfizer initiate patent infringement action hatchwaxman act generic filer district court district delaware april august patent trademark office grant patent term restoration composition matter patent restore term eliquis composition matter patent bmss basis project loe february november bms settle number anda filer settlement affect bmss project loe eliquis trial remain anda filer take place late posttrial briefing expect complete end february decision expect time plavix australia sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate mg tablets australia genrx subsidiary apotex inc subsequently change apotex genrxapotex august genrxapotex file application federal court australia seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court australia grant sanofis injunction subsidiary bms subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidated genrxapotex case august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid bms sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim genrxapotex appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim september court hold claim patent invalid march high court australia deny request bms sanofi hear appeal court decision case remand federal court proceeding relate damage seek genrx apotex bms genrxapotex settle genrxapotex case dismiss australian government intervene matter seek maximum damage million aud million plus interest split bms sanofi allege loss experience pay high price brand plavix period injunction place bms sanofi dispute australian government entitle damage trial conclude september bms expect decision pomalyst celgene receive notice letter behalf teva pharmaceuticals usa inc apotex inc apotex apotex corp hetero labs limited hetero labs limited unitv hetero drugs limited hetero usa inc hetero aurobindo pharma ltd mylan pharmaceuticals inc breckenridge pharmaceutical inc notify celgene file anda contain paragraph iv certification seek approval market generic version pomalyst response celgene file patent infringement action company district court district new jersey assert certain fda orange bookliste patent litigation assert nonfda orange bookliste patent company file answer counterclaim andor declaratory judgment action allege assert patent invalid unenforceable andor infringe litigation subsequently consolidate trial schedule july august celgene subsequently file additional patent infringement action district court district new jersey company assert certain patent list fda orange book cover polymorphic form pomalidomide company file answer andor counterclaim allege patent invalid andor infringe action court order party ready trial april june celgene receive notice letter dr reddys laboratories ltd dr reddys laboratories inc drl notifying celgene file anda contain paragraph iv certification seek approval market generic version pomalyst response celgene initiate patent infringement action drl district court district new jersey assert certain fda orange bookliste patent drl file answer counterclaim allege patent invalid andor infringe trial date set revlimid canada celgene receive notice allegation july natco pharma canada inc natco canada notify celgene file natco canada separate andas canadas minister health respect certain celgene canadian letter patent natco canada seek market generic version revlimid canada response celgene initiate patent infringement action federal court canada seek injunction natco allege assert patent invalid andor infringe trial schedule start march celgene receive notice allegation october apotex notify celgene file apotexs anda canadas minister health respect certain celgene canadian letter patent apotex seek market generic version revlimid canada response celgene initiate patent infringement action federal court canada seek injunction celgene enter confidential settlement agreement apotex concern case action discontinue november revlimid celgene receive notice letter behalf drl zydus pharmaceuticals usa inc cipla ltd india apotex sun pharma global fze sun pharma global inc sun pharmaceutical industries inc sun pharmaceutical industry limited hetero mylan pharmaceuticals inc mylan inc mylan nv aurobindo pharma limited eugia pharma speciality limited aurobindo pharma usa inc aurolife pharma llc notify celgene file anda contain paragraph iv certification seek approval market generic version revlimid response celgene file patent infringement action company district court district new jersey assert certain fda orange bookliste patent litigation assert non fda orange bookliste patent company file answer andor counterclaim allege assert patent invalid unenforceable andor infringe litigation different schedule trial date set litigation case early potential trial date drl respect certain fda orange bookliste patent final pretrial conference case set june sprycel europe january opposition division epo revoke european patent patent cover dasatinib active ingredient sprycel decision uphold epo board appeal february orphan drug exclusivity datum exclusivity sprycel eu expire november epo board appeal decision affect validity bmss sprycel patent outside europe include different patent cover monohydrate form dasatinib use dasatinib treat cml additionally february epo board appeal reverse remand invalidity decision european patent claim use dasatinib treat cml epos opposition division revoke october december epos opposition division uphold validity patent direct use dasatinib treat cml expire number generic company launch generic dasatinib product europe indication sprycel august bm receive notice letter dr reddys laboratories inc notifying bm file anda contain paragraph iv certification seek approval generic version sprycel challenge fda orange bookliste monohydrate form patent expire response bms initiate patent infringement lawsuit hatchwaxman act district court district new jersey trial date set bms enter settlement agreement apotex patent infringement suit cover monohydrate form dasatinib apotex launch generic dasatinib monohydrate anda product september early certain circumstance price sale promotional practice litigation plavix state attorney general lawsuit bms certain sanofi entity defendant consumer protection andor false advertising action bring attorney general hawaii new mexico relate sale promotion plavix hawaii matter currently schedule trial product liability litigation bms party product liability lawsuit plaintiff case seek damage relief ground allege personal injury economic loss previously disclose addition lawsuit bms face unfiled claim involve product abilify bms otsuka codefendant product liability litigation relate abilify plaintiff allege abilify cause engage compulsive gambling impulse control disorder case file state federal court additional case pende canada judicial panel multidistrict litigation consolidated federal court case pretrial purpose district court northern district florida february bms otsuka enter master settlement agreement establish propose settlement program resolve abilify compulsivity claim file january mdl state court include california new jersey approximately case remain pende behalf plaintiff choose participate settlement program file claim settlement cutoff date byetta amylin subsidiary bms lilly codefendant product liability litigation relate byetta date approximately separate lawsuit pende behalf approximately active plaintiff include pende settlement include injury plaintiff claim spouse andor beneficiary court majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer case claim alleged wrongful death majority case pende federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendant motion summary judgment base federal preemption grant mdl jccp november ninth circuit reverse mdl summary judgment order remand case mdl november california court appeal reverse state court summary judgment order remand case jccp proceeding amylin product liability insurance cover substantial number claim involve byetta exhaust bmss global diabete business divestiture bms sell byetta astrazeneca february additional liability amylin respect byetta expect share astrazeneca onglyza bms astrazeneca codefendant product liability litigation relate onglyza plaintiff assert claim include claim wrongful death result heart failure cardiovascular injury allege cause use onglyza january claim pende state federal court behalf approximately individual allege ingest product suffer injury february judicial panel multidistrict litigation order federal case transfer mdl district court eastern district kentucky significant majority claim pende mdl bmss global diabete business divestiture bms sell onglyza astrazeneca february potential liability respect onglyza expect share astrazeneca security litigation bms security class action february separate putative class action complaint file district northern district california district court southern district new york bms bmss chief executive officer giovanni caforio bmss chief financial officer time charle bancroft certain current executive bms case california voluntarily dismiss remain complaint allege violation security law bmss disclosure relate checkmate clinical trial lung cancer september court grant bmss motion dismiss allow plaintiff leave file amend complaint october plaintiff file amend complaint bms move dismiss amend complaint celgene security class action begin march putative class action file celgene certain officer district court district new jersey celgene security class action complaint allege defendant violate federal security law make misstatement andor omission concern trial ge celgene outlook project sale otezla new drug application ozanimod court consolidate action appoint lead plaintiff lead counsel coliaison counsel putative class february defendant file motion dismiss plaintiff amend complaint december court deny motion dismiss grant motion dismiss include claim arise allege misstatement ge court give plaintiff leave replead dismiss claim elect dismiss claim dismiss prejudice trial date set claim survive court order gerold derivative action october sam baran gerold file shareholder derivative complaint certain member celgene board director superior court new jersey complaint allege defendant breach certain fiduciary duty relate thing action respect clinical trial ge otezla new drug application ozanimod ii breach defendant cause celgene waste corporate asset defendant unjustly enrich october defendant remove matter district court district new jersey january party enter stipulation propose order voluntarily dismiss matter prejudice court enter january saratoga derivative action july saratoga advantage trust health biotechnology portfolio saratoga file shareholder derivative complaint certain member celgene board director district court district new jersey complaint allege certain defendant misrepresentation omission material fact concern thing clinical trial ge sale otezla celgene fiscal guidance new drug application ozanimod ii defendant fail adequately supervise celgene regard clinical trial ge sale otezla celgene fiscal guidance new drug application ozanimod promotion marketing revlimid saratoga agree stay defendant obligation answer respond allegation complaint deference celgene security class action august court enter order stay proceeding disposition motion dismiss celgene security class action order administratively terminate proceeding litigation average manufacturer price litigation bms defendant qui tam whistleblower lawsuit district court eastern district pennsylvania government decline intervene complaint allege bms inaccurately report average manufacturer price center medicare medicaid services lower owe similar claim file company january bms reach agreement principle resolve matter subject negotiation definitive settlement agreement contingency bms provide assurance effort reach final settlement successful hiv medication antitrust lawsuit bms manufacturer hiv medication defendant relate lawsuit bring indirect purchaser direct purchaser district court northern district california indirect purchaser district court southern district florida case allege defendant agreement develop sell fixeddose combination product treatment hiv include atripla evotaz violate antitrust law indirect purchaser complaint file florida transfer consolidated matter pende northern district california bms move intend dismiss complaint humana litigation humana inc humana file lawsuit celgene pike county circuit court commonwealth kentucky humanas complaint allege celgene engage unlawful offlabel marketing connection sale thalomid revlimid assert claim celgene fraud breach contract negligent misrepresentation unjust enrichment violation new jersey racketeer influence corrupt organization act complaint seek thing treble punitive damage injunctive relief attorney fee cost april celgene file motion dismiss humanas complaint court deny january trial date set march humana file separate lawsuit celgene district court district new jersey humanas complaint allege celgene violate antitrust consumer protection unfair competition law delay prevent generic competition thalomid revlimid brand drug include allegedly refuse sell sample product generic manufacturer purpose bioequivalence testing intend include andas approval market generic version product b allegedly bring unjustified patent infringement lawsuit procure invalid patent andor enter anticompetitive patent settlement c allegedly secure exclusive supply contract supply thalidomide active pharmaceutical ingredient complaint purport assert claim behalf humana subsidiary capacity include direct purchaser indirect purchaser seek thing treble punitive damage injunctive relief attorney fee cost celgene file motion dismiss humanas complaint court stay discovery pende adjudication motion trial date set thalomid revlimid antitrust litigation begin november certain putative class action lawsuit file celgene district court district new jersey allege celgene violate antitrust consumer protection unfair competition law allegedly secure exclusive supply contract allege purpose prevent generic manufacturer secure supply thalidomide active pharmaceutical ingredient b allegedly refuse sell sample thalomid revlimid brand drug generic manufacturer allege purpose bioequivalence test necessary anda submit fda approval market generic version product c allegedly bring unjustified patent infringement lawsuit order allegedly delay approval propose generic version thalomid revlimid andor allegedly enter settlement patent infringement lawsuit certain generic manufacturer allegedly anticompetitive effect plaintiff behalf putative class thirdparty payer seek injunctive relief damage lawsuit consolidate master action purpose october plaintiff file motion certification damage class law thirteen state district columbia nationwide injunction class celgene file opposition plaintiff motion motion judgment pleading dismiss state law claim plaintiff long seek represent class october court deny plaintiff motion class certification celgene motion judgment pleading december plaintiff file new motion class certification celgene oppose july party reach settlement putative class plaintiff claim dismiss prejudice december certain thirdparty payor member settlement class refuse release potential claim participate settlement celgene exercise right terminate settlement agreement trial date set government investigation like pharmaceutical company bms certain subsidiary subject extensive regulation national state local authority country bms operate result bms time time subject governmental regulatory inquiry investigation threaten legal action proceeding possible criminal charge substantial fine andor civil penalty result government regulatory investigation environmental proceeding previously report bms party environmental proceeding matter responsible state federal foreign law include cercla certain cost investigate andor remediate contamination result past industrial activity bmss current site waste disposal reprocess facility operate party cercla matter respect cercla matter bms responsible state federal foreign law bm typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party bms accrue liability probable reasonably estimable bms estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party include estimate cost additional probable loss associate previously disclose north brunswick township high school remediation site note select quarterly financial datum unaudite year end december dollar million share datum quarter second quarter quarter fourth quarterd yeard total revenue gross margin net earningsloss net earningsloss attributable noncontrolle interest bms earningsloss common share basica earningsloss common share diluteda cash dividend declare common share cash cash equivalent marketable debt securitiesb total asset longterm debtc equity year end december dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earning common share basica earning common share diluteda cash dividend declare common share cash cash equivalent marketable debt securitiesb total asset longterm debtc equity earning share quarter add amount year period compute discrete basis b marketable debt security include current noncurrent asset c longterm debt include current portion commence november celgene operation include consolidated financial statement refer note acquisition divestiture license arrangement additional information follow specify item affect comparability result year end december dollar million quarter second quarter quarter fourth quarter year inventory purchase price accounting adjustment employee compensation charge site exit cost cost product sell employee compensation charge site exit cost marketing sell administrative license asset acquisition charge iprd impairment employee compensation charge site exit cost research development amortization acquire intangible asset interest expense pension postretirement royalty licensing income divestiture gainslosse acquisition expense contingent value right investment income integration expense provision restructure equity investment gainslosse litigation settlement incomeexpense net increase pretax income income taxis item income taxis attribute otezla divestiture income taxis increase net earning year end december dollar million quarter second quarter quarter fourth quarter year site exit cost cost product sell marketing sell administrative license asset acquisition charge site exit cost research development pension postretirement royalty licensing income divestiture gain provision restructure equity investment gainslosse litigation settlement intangible asset impairment incomeexpense net increasedecrease pretax income income taxis item income taxis attribute tax reform income taxis increasedecrease net earning report independent register public accounting firm shareholder board director bristolmyers squibb company opinion financial statement audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december relate note collectively refer financial statement opinion financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states pcaob company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion critical audit matter critical audit matter communicate matter arise currentperiod audit financial statement communicate require communicate audit committee relate account disclosure material financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate grosstonet rebate accrual medicaid medicare manage healthcare refer note revenue financial statement critical audit matter description fully disclose note financial statement company reduce gross product sale list price time revenue recognize expect chargeback discount rebate sale allowance product return refer grosstonet gtn adjustment reduction attribute commercial arrangement manage healthcare organization government program mandate reduction list price chargeback cash discount reflect reduction receivables settle issuance credit customer rebate discount adjustment reflect liability settle cash payment customer certain gtn liability relate medicaid medicare manage healthcare organization rebate program gtn rebate accrual involve use significant assumption judgment calculation significant assumption judgment include consideration legal interpretation applicable law regulation historical claim experience payer channel mix current contract price unbilled claim claim submission time lag inventory level distribution channel give complexity involve determine significant assumption calculate gtn rebate accrual auditing estimate involve especially subjective judgment critical audit matter address audit audit procedure relate gtn rebate accrual include follow evaluate appropriateness consistency company method assumption calculate gtn rebate accrual test effectiveness internal control review company estimation model include underlying assumption key input company process calculate gtn rebate accrual test mathematical accuracy gtn rebate accrual test significant assumption key input calculate gtn rebate accrual evaluate company ability estimate gtn rebate accrual accurately compare actual amount incur gtn rebate accrual historical estimate test overall reasonableness gtn rebate accrual record period end develop expectation comparison actual record balance involve audit professional industry quantitative analytic experience assist perform auditing procedure taxis unrecognize tax benefit liabilitie transfer pricing refer note income taxis financial statement critical audit matter description fully disclose note financial statement company recognize certain income tax benefit associate transaction operate company relate foreign affiliate income tax benefit estimate base transfer pricing agreement thirdparty transfer pricing study company judgment morelikelythannot benefit realize tax benefit ultimately realize company determine judgment accrue unrecognized tax benefit liability amount recognize unrecognized tax benefit liability relate transfer pricing significantly affect subsequent period factor change tax law identification additional relevant fact change company judgment measurement tax benefit ultimate settlement tax authority give complexity associate assumption calculate unrecognized tax benefit liability relate transfer pricing couple significant judgment company determination auditing estimate involve especially subjective judgment critical audit matter address audit audit procedure relate unrecognized tax benefit liability relate transfer pricing include follow evaluate appropriateness consistency company method assumption identification recognition measurement disclosure unrecognized tax benefit liability test effectiveness internal control review underlie assumption key input company process calculate unrecognized tax benefit liability obtain understand company relate party transaction transfer pricing policy test mathematical accuracy unrecognized tax benefit liability test completeness unrecognized tax benefit liability test reasonableness underlie tax position amount accrue selection unrecognized tax benefit liability review company evaluation relevant fact tax law associate tax position test significant assumption input calculate unrecognized tax benefit liability reference party datum information produce entity understand transfer pricing principle tax law inquire management evaluate company appropriately consider new information significantly change recognition measurement disclosure unrecognized tax benefit liability involve income tax specialist audit professional industry experience assist perform auditing procedure valuation certain intangible asset celgene corporation acquisition refer note accounting policy recently issue accounting standard note acquisition divestiture license arrangement financial statement critical audit matter description company complete acquisition celgene corporation celgene approximately billion november company account acquisition business combination accordingly purchase price allocate preliminary basis asset acquire liability assume base respective fair value include currentlymarketed product right intangible asset product right inprocess research development intangible asset iprd asset company estimate fair value product right iprd asset discount cash flow method fair value determination product right iprd asset require company significant estimate assumption relate forecasted future cash flow selection discount rate identify valuation certain product right iprd asset celgene acquisition critical audit matter significant estimate assumption company determine fair value asset auditing estimate assumption relate valuation certain product right iprd asset require high degree auditor judgment increase extent effort include involvement valuation specialist perform audit procedure evaluate reasonableness management forecast future cash flow selection discount rate product right iprd asset critical audit matter address audit audit procedure relate valuation certain product right iprd asset celgene acquisition include forecast future cash flow selection discount rate certain product right iprd asset include follow evaluate appropriateness consistency company method assumption forecast future cash flow select discount rate test effectiveness control valuation certain product right iprd asset include company control forecast future cash flow selection discount rate perform sensitivity analyse significant assumption valuation model evaluate change fair value result change significant assumption assess reasonableness company forecast future cash flow compare forecast historical result operation certain peer company andor internal external market study assistance valuation specialist evaluate reasonableness discount rate test source information underlie determination discount rate test mathematical accuracy calculation develop range independent estimate compare discount rate select management evaluate forecast future cash flow consistent evidence obtain area audit deloitte touche llp parsippany new jersey february serve company auditor item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure define exchange act rule ae de end period cover base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting define exchange act rule af supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate exclude scope assessment internal control financial reporting operation relate asset celgene corporation acquire november december period acquisition december total asset total revenue subject celgene internal control financial reporting represent bms consolidated total asset total revenue year end december base assessment bms management believe december company internal control financial reporting effective base criterion deloitte touche llp independent register public accounting firm audit company financial statement include report form k issue report effectiveness company internal control financial reporting december include change internal control financial reporting december management process evaluate integrate internal control acquire celgene business company exist operation control enhance implement integrate celgene business change company internal control financial reporting year end december materially affect reasonably likely materially affect company internal control financial reporting item b information report independent register public accounting firm shareholder board director bristolmyers squibb company opinion internal control financial reporting audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso audit accordance standard public company accounting oversight board united states pcaob consolidate financial statement year end december company report date february express unqualified opinion consolidated financial statement describe management report internal control financial reporting management exclude assessment internal control financial reporting celgene corporation acquire november financial statement constitute total asset total revenue respectively consolidated financial statement amount year end december accordingly audit include internal control financial report celgene corporation basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp parsippany new jersey february iii item director executive officer registrant reference proxy statement respect director incorporate reference hereof response information require item b information require item respect executive officer include ia reliance general instruction g instruction item b regulation sk incorporate reference hereof response information require item item executive compensation reference proxy statement respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement respect auditor fee incorporate reference hereof response information require item iv item